BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer 2017;17:637-58. [DOI: 10.1038/nrc.2017.84] [Cited by in Crossref: 440] [Cited by in F6Publishing: 491] [Article Influence: 73.3] [Reference Citation Analysis]
Number Citing Articles
1 Yang J, Hou C, Wang H, Perez EA, Do-Umehara HC, Dong H, Arunagiri V, Tong F, Van Scoyk M, Cho M, Liu X, Ge X, Winn RA, Ridge KM, Wang X, Chandel NS, Liu J. Miz1 promotes KRAS-driven lung tumorigenesis by repressing the protocadherin Pcdh10. Cancer Lett 2023;555:216025. [PMID: 36538983 DOI: 10.1016/j.canlet.2022.216025] [Reference Citation Analysis]
2 Kashefizadeh A, Kazemizadeh H. Immunogenic cell death (ICD)-inducers in non-small-cell lung carcinoma (NSCLC): current knowledge and future perspective. Clin Transl Oncol 2023;25:316-22. [PMID: 36180811 DOI: 10.1007/s12094-022-02949-x] [Reference Citation Analysis]
3 Zhu J, Cao K, Zhao M, Ma K, Jiang X, Bai Y, Ling X, Ma J. Improvement of ACK1-targeted therapy efficacy in lung adenocarcinoma using chloroquine or bafilomycin A1. Mol Med 2023;29:6. [PMID: 36647009 DOI: 10.1186/s10020-023-00602-z] [Reference Citation Analysis]
4 Chhouri H, Alexandre D, Grumolato L. Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer. Cancers (Basel) 2023;15. [PMID: 36672453 DOI: 10.3390/cancers15020504] [Reference Citation Analysis]
5 Li X, Wu F. Mesenchymal stem cell-derived extracellular vesicles transfer miR-598 to inhibit the growth and metastasis of non-small-cell lung cancer by targeting THBS2. Cell Death Discov 2023;9:3. [PMID: 36609437 DOI: 10.1038/s41420-022-01283-z] [Reference Citation Analysis]
6 Wang Y, Zhang Y, Chen R, Tian X. Autocrine EGF and TGF-α promote primary and acquired resistance to ALK/c-Met kinase inhibitors in non-small-cell lung cancer. Pharmacol Res Perspect 2023;11:e01047. [PMID: 36583451 DOI: 10.1002/prp2.1047] [Reference Citation Analysis]
7 Chandrasekharan A. Driver Mutations in Lung Cancer-Mapping the Way Forward. South Asian J Cancer 2022;11:181-2. [PMID: 36588608 DOI: 10.1055/s-0042-1758549] [Reference Citation Analysis]
8 Chen M, Xu Y, Zhao J, Liu X, Liu X, Zhang D, Shi Y, Zhang L, Zhong W, Wang M. Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non-small-Cell Lung Cancer Patients. Clin Lung Cancer 2022:S1525-7304(22)00291-1. [PMID: 36635116 DOI: 10.1016/j.cllc.2022.12.003] [Reference Citation Analysis]
9 Su M, Chen Y, Jia L, Zhang Z. Camptothecin-Loaded and Manganese Dioxide-Coated Polydopamine Nanomedicine Used for Magnetic Resonance Imaging Diagnosis and Chemo-Photothermal Therapy for Lung Cancer. Int J Nanomedicine 2022;17:6687-705. [PMID: 36597434 DOI: 10.2147/IJN.S359300] [Reference Citation Analysis]
10 Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov 2022. [PMID: 36509911 DOI: 10.1038/s41573-022-00615-z] [Reference Citation Analysis]
11 Wang Z, Xing Y, Li B, Li X, Liu B, Wang Y. Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. Mol Biomed 2022;3:42. [PMID: 36508072 DOI: 10.1186/s43556-022-00107-x] [Reference Citation Analysis]
12 Zhou Y, Xiang S, Yang F, Lu X. Targeting Gatekeeper Mutations for Kinase Drug Discovery. J Med Chem 2022;65:15540-58. [PMID: 36395392 DOI: 10.1021/acs.jmedchem.2c01361] [Reference Citation Analysis]
13 Wu J, Lin Z. Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance. Int J Mol Sci 2022;23. [PMID: 36499382 DOI: 10.3390/ijms232315056] [Reference Citation Analysis]
14 Kim S, Kim BY, Lee KH. Synergistic effect of anticancer drug resistance and Wnt3a on primary ciliogenesis in A549 cell-derived anticancer drug-resistant subcell lines. Biochemical and Biophysical Research Communications 2022;635:1-11. [DOI: 10.1016/j.bbrc.2022.10.026] [Reference Citation Analysis]
15 Yu N, Hwang M, Lee Y, Song BR, Kang EH, Sim H, Ahn B, Hwang KH, Kim J, Hong S, Kim S, Park C, Han J. Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer.. [DOI: 10.21203/rs.3.rs-2295528/v1] [Reference Citation Analysis]
16 Zhong WX, Wei XF. Coexistence of anaplastic lymphoma kinase rearrangement in lung adenocarcinoma harbouring epidermal growth factor receptor mutation: A single-center study. World J Clin Cases 2022; 10(33): 12164-12174 [DOI: 10.12998/wjcc.v10.i33.12164] [Reference Citation Analysis]
17 Liu B, Dong C, Chen Q, Fan Z, Zhang Y, Wu Y, Cui T, Liu F. Circ_0007534 as new emerging target in cancer: Biological functions and molecular interactions. Front Oncol 2022;12:1031802. [PMID: 36505874 DOI: 10.3389/fonc.2022.1031802] [Reference Citation Analysis]
18 Lara MS, Gubens MA, Bacaltos B, Daran L, Lim SL, Li T, Gandara DR, Bivona TG, Riess JW, Blakely CM. Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC. JTO Clin Res Rep 2022;3:100436. [PMID: 36545322 DOI: 10.1016/j.jtocrr.2022.100436] [Reference Citation Analysis]
19 Zhang S, Lu Y, He X, Su Y, Hu F, Wei X, Pan M, Zhou Q, Yang W. Lutein inhibits tumor progression through the ATR /Chk1/p53 signaling pathway in non‐small cell lung cancer. Phytotherapy Research 2022. [DOI: 10.1002/ptr.7682] [Reference Citation Analysis]
20 Huang X, Lu Z, He M, Feng Y, Yu S, Shen B, Lu J, Wu P, Pan B, Ding H, Chen C, Sun Y. A Prognostic Risk Model of a Novel Oxidative Stress-Related Signature Predicts Clinical Prognosis and Demonstrates Immune Relevancy in Lung Adenocarcinoma. Oxidative Medicine and Cellular Longevity 2022;2022:1-43. [DOI: 10.1155/2022/2262014] [Reference Citation Analysis]
21 Li C, Qiu Y, Zhang Y. Research Progress on Therapeutic Targeting of Cancer-Associated Fibroblasts to Tackle Treatment-Resistant NSCLC. Pharmaceuticals 2022;15:1411. [DOI: 10.3390/ph15111411] [Reference Citation Analysis]
22 Agbektas T, Zontul C, Ozturk A, Huseynzada A, Ganbarova R, Hasanova U, Cinar G, Tas A, Kaya S, Chtita S, Silig Y. EFFECT of AZOMETHINE GROUP CONTAINING COMPOUNDS on GENE PROFILES in Wnt and MAPK SIGNAL PATTERNS in LUNG CANCER CELL LINE: In Silico and In Vitro ANALYSES. Journal of Molecular Structure 2022. [DOI: 10.1016/j.molstruc.2022.134619] [Reference Citation Analysis]
23 Liu Z, Li X, Gao J, Yin P, Teng Y, Yu P. The therapeutic inhibition of topoisomerase inhibitor and crizotinib combination in EGFR wild and mutant lung cancer cells. Biochemical Pharmacology 2022;205:115294. [DOI: 10.1016/j.bcp.2022.115294] [Reference Citation Analysis]
24 Shi B, An K, Wang Y, Fei Y, Guo C, Cliff Zhang Q, Yang Y, Tian X, Kan Q. RNA Structural Dynamics Modulate EGFR-TKI Resistance Through Controlling YRDC Translation in NSCLC Cells. Genomics, Proteomics & Bioinformatics 2022. [DOI: 10.1016/j.gpb.2022.10.006] [Reference Citation Analysis]
25 Wang Z, Lei P, Li Z, Han X, Yang F, Su T, Meng C, Hou Z, Liu H. Proteomic and Phosphoproteomic Analyses Reveal the Oncogenic Role of PTK7-NDRG1 Axis in Non-small-cell Lung Cancer Cell Resistance to AZD9291. ACS Chem Biol 2022;17:2849-62. [PMID: 36205702 DOI: 10.1021/acschembio.2c00479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Xu Y, Gu L, Li Y, Zhao R, Jian H, Xie W, Liu L, Wu H, Ren F, Han Y, Lu S. Integrative genomic analysis of drug resistance in MET exon 14 skipping lung cancer using patient-derived xenograft models. Front Oncol 2022;12:1024818. [DOI: 10.3389/fonc.2022.1024818] [Reference Citation Analysis]
27 Abbasian MH, Ardekani AM, Sobhani N, Roudi R. The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment. Cancers 2022;14:5144. [DOI: 10.3390/cancers14205144] [Reference Citation Analysis]
28 Guo R, Chen Y, Zhang C, Jin S, Li J, Dai J, Zhang Z. Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in non-small cell lung cancer.. [DOI: 10.21203/rs.3.rs-2135034/v1] [Reference Citation Analysis]
29 Shi B, An K, Wang Y, Fei Y, Guo C, Zhang QC, Yang Y, Tian X, Kan Q. RNA structural dynamics modulate EGFR-TKIs resistance through controllingYRDCtranslation in NSCLC cells.. [DOI: 10.1101/2022.10.17.512459] [Reference Citation Analysis]
30 Peng Y, Wang Z, Cai J, Dong X, Du Q, Yang D. GEMIN6 Overexpression Correlates with the Low Immune Cell Infiltration and Poor Prognosis in Lung Adenocarcinoma. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/1930604] [Reference Citation Analysis]
31 Girard N. New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer. Curr Treat Options Oncol 2022. [PMID: 36242712 DOI: 10.1007/s11864-022-01022-7] [Reference Citation Analysis]
32 Guo H, Zhang J, Qin C, Yan H, Liu T, Hu H, Tang S, Tang S, Zhou H. Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives. Cells 2022;11:3200. [DOI: 10.3390/cells11203200] [Reference Citation Analysis]
33 Gao J, Ao YQ, Zhang LX, Deng J, Wang S, Wang HK, Jiang JH, Ding JY. Exosomal circZNF451 restrains anti-PD1 treatment in lung adenocarcinoma via polarizing macrophages by complexing with TRIM56 and FXR1. J Exp Clin Cancer Res 2022;41:295. [PMID: 36209117 DOI: 10.1186/s13046-022-02505-z] [Reference Citation Analysis]
34 Cadranel J, Fallet V, Baldacci S, Duruisseaux M, Cortot A. Algorithme thérapeutique des cancers bronchiques non à petites cellules étendus avec mutation de l’EGR. Revue des Maladies Respiratoires Actualités 2022;14:2S189-2S208. [DOI: 10.1016/s1877-1203(22)00119-7] [Reference Citation Analysis]
35 Remon J, Hendriks LE, Mountzios G, García-campelo R, Saw SP, Uprety D, Recondo G, Villacampa G, Reck M. MET alterations in NSCLC—Current Perspectives and Future Challenges. Journal of Thoracic Oncology 2022. [DOI: 10.1016/j.jtho.2022.10.015] [Reference Citation Analysis]
36 Alam K, Mazumder A, Sikdar S, Zhao Y, Hao J, Song C, Wang Y, Sarkar R, Islam S, Zhang Y, Li A. Streptomyces: The biofactory of secondary metabolites. Front Microbiol 2022;13:968053. [DOI: 10.3389/fmicb.2022.968053] [Reference Citation Analysis]
37 Ling B, Zhang Z, Xiang Z, Cai Y, Zhang X, Wu J. Advances in the application of proteomics in lung cancer. Front Oncol 2022;12:993781. [DOI: 10.3389/fonc.2022.993781] [Reference Citation Analysis]
38 Cai J, Zheng Y, Dong L, Zhang X, Huang Y. Circular RNA hsa_circ_0018189 drives non-small cell lung cancer growth by sequestering miR-656-3p and enhancing xCT expression. J Clin Lab Anal 2022;:e24714. [PMID: 36164726 DOI: 10.1002/jcla.24714] [Reference Citation Analysis]
39 Qin H, Ke J, Dong S, Li H, Zhu K, Fu S, Shao Q, Li Z. Effect of thoracic radiotherapy dose on the prognosis of advanced lung adenocarcinoma harboring EGFR mutations. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-10095-4] [Reference Citation Analysis]
40 Ando T, Okamoto K, Shintani T, Yanamoto S, Miyauchi M, Gutkind JS, Kajiya M. Integrating Genetic Alterations and the Hippo Pathway in Head and Neck Squamous Cell Carcinoma for Future Precision Medicine. JPM 2022;12:1544. [DOI: 10.3390/jpm12101544] [Reference Citation Analysis]
41 Jiang J, Zhao C, Zhang F, Liu Z, Zhou K, Ren X, Wan Y. ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis. BMJ Open 2022;12:e060782. [PMID: 36123063 DOI: 10.1136/bmjopen-2022-060782] [Reference Citation Analysis]
42 Hwang G, Yuen JG, Fesler A, Farley H, Haley JD, Ju J. Development of a 5-FU Modified miR-129 Mimic as a Therapeutic for Non-Small Cell Lung Cancer.. [DOI: 10.1101/2022.09.16.508317] [Reference Citation Analysis]
43 Li F, Song Q, Zhang Y, Wang X, Cao L, Li N, Zhao L, Zhang S, Zhuang X. Identifying the EMT-related signature to stratify prognosis and evaluate the tumor microenvironment in lung adenocarcinoma. Front Genet 2022;13:1008416. [DOI: 10.3389/fgene.2022.1008416] [Reference Citation Analysis]
44 Blinova EV, Epishkina AV, Tumutolova OM, Deryabina ON, Skachilova SY, Kudriavtsev MY, Shikh EV, Vavilova OS, Gilevskaya YS, Brykin GV, Makhrova AA, Blinov DS. Antitumor activity of the novel pyridine derivative. RRP 2022;8:81-86. [DOI: 10.3897/rrpharmacology.8.89997] [Reference Citation Analysis]
45 Mengyan X, Kun D, Xinming J, Yutian W, Yongqian S. Identification and verification of hub genes associated with the progression of non-small cell lung cancer by integrated analysis. Front Pharmacol 2022;13:997842. [DOI: 10.3389/fphar.2022.997842] [Reference Citation Analysis]
46 Esposito R, Polidori T, Meise DF, Pulido-quetglas C, Chouvardas P, Forster S, Schaerer P, Kobel A, Schlatter J, Kerkhof E, Roemmele M, Rice ES, Zhu L, Lanzós A, Guillen-ramirez HA, Basile G, Carrozzo I, Vancura A, Ullrich S, Andrades A, Harvey D, Medina PP, Ma PC, Haefliger S, Wang X, Martinez I, Ochsenbein AF, Riether C, Johnson R. Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities. Cell Genomics 2022;2:100171. [DOI: 10.1016/j.xgen.2022.100171] [Reference Citation Analysis]
47 Zhang W, Ke Y, Liu X, Jin M, Huang G. Drug resistance in NSCLC is associated with tumor micro-environment. Reprod Biol 2022;22:100680. [PMID: 35926330 DOI: 10.1016/j.repbio.2022.100680] [Reference Citation Analysis]
48 Ma Y, Zhao H, Xue J, Liu L, Yang N, Zhang Y, Yang H, Hong S, Xiong Y, Zhang Z, Zeng L, Pan H, Zhou C, Zhang Y, Wang X, Han X, Wan X, Shao Y, Liu J, Yang Y, Huang Y, Zhao Y, Fang W, Li S, Zhang L. First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements. Eur J Cancer 2022;173:238-49. [PMID: 35940055 DOI: 10.1016/j.ejca.2022.06.037] [Reference Citation Analysis]
49 Park S, Cho EA, Chun JN, Lee DY, Lee S, Kim MY, Bae SM, Jo SI, Lee SH, Park HH, Kim TM, So I, Kim SY, Jeon JH. Crizotinib attenuates cancer metastasis by inhibiting TGFβ signaling in non-small cell lung cancer cells. Exp Mol Med 2022. [PMID: 35999455 DOI: 10.1038/s12276-022-00835-8] [Reference Citation Analysis]
50 Girard N, Basse C. EGFR-mutant NSCLC: monitoring the molecular evolution of tumors in 2022. Expert Rev Anticancer Ther 2022. [PMID: 35993098 DOI: 10.1080/14737140.2022.2116004] [Reference Citation Analysis]
51 Hashimoto S, Hashimoto A, Muromoto R, Kitai Y, Oritani K, Matsuda T. Central Roles of STAT3-Mediated Signals in Onset and Development of Cancers: Tumorigenesis and Immunosurveillance. Cells 2022;11:2618. [PMID: 36010693 DOI: 10.3390/cells11162618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Zhang Y, Yuan J, Guo M, Xiang R, Wang X, Xie T, Zhuang X, Li Q, Lai Q, Yang Y. miR-657 Targets SRCIN1 via the Slug Pathway to Promote NSCLC Tumor Growth and EMT Induction. Disease Markers 2022;2022:1-15. [DOI: 10.1155/2022/4842454] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Remsing Rix LL, Sumi NJ, Hu Q, Desai B, Bryant AT, Li X, Welsh EA, Fang B, Kinose F, Kuenzi BM, Chen YA, Antonia SJ, Lovly CM, Koomen JM, Haura EB, Marusyk A, Rix U. IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells. Sci Signal 2022;15:eabj5879. [PMID: 35973030 DOI: 10.1126/scisignal.abj5879] [Reference Citation Analysis]
54 Kusaba Y, Takeda Y, Abe S, Tsukada A, Naka G. T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review. Medicine (Baltimore) 2022;101:e29682. [PMID: 35960133 DOI: 10.1097/MD.0000000000029682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Munnik C, Xaba MP, Malindisa ST, Russell BL, Sooklal SA. Drosophila melanogaster: A platform for anticancer drug discovery and personalized therapies. Front Genet 2022;13:949241. [DOI: 10.3389/fgene.2022.949241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Pang Z, Ye L. Illuminating spatial pharmacology with in situ drug imaging. Clin Transl Med 2022;12:e1024. [PMID: 36030504 DOI: 10.1002/ctm2.1024] [Reference Citation Analysis]
57 Willard N, Sholl L, Aisner D. Panel Sequencing for Targeted Therapy Selection in Solid Tumors. Clinics in Laboratory Medicine 2022. [DOI: 10.1016/j.cll.2022.04.004] [Reference Citation Analysis]
58 Vaquero J, Pavy A, Gonzalez-sanchez E, Meredith M, Arbelaiz A, Fouassier L. Genetic alterations shaping tumor response to anti-EGFR therapies. Drug Resistance Updates 2022. [DOI: 10.1016/j.drup.2022.100863] [Reference Citation Analysis]
59 Pearson AD, Gaspar N, Janeway K, Campbell-Hewson Q, Lawlor ER, Copland C, Karres D, Norga K, Benzaghou F, Weiner S, Weigel B, Weiss AR, Strauss SJ, Smith M, Setty BA, Seibel N, Scobie N, Pappo A, Okpara CE, Nysom K, McDonough J, Marshall LV, Ludwinski D, Ligas F, Lesa G, Knudsen S, Kauh J, Hsieh A, Heenen D, Hawkins DS, Graham A, Garmey E, DuBois SG, Fox E, Donoghue M, de Rojas T, Chung J, Casanova M, Brennan B, Bishop M, Buenger V, Reaman G, Vassal G. Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer 2022;173:71-90. [PMID: 35863108 DOI: 10.1016/j.ejca.2022.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Papageorgiou S, Pashley SL, O'Regan L, Khan S, Bayliss R, Fry AM. Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer. Cancers (Basel) 2022;14:3452. [PMID: 35884511 DOI: 10.3390/cancers14143452] [Reference Citation Analysis]
61 Wang G, Xie Y, Qian X, Zhang X, Shan Y, Zhang M, Li J, Zhang Z, Li Y. Poly (maleic anhydride-alt-1-octadecene)-based bioadhesive nanovehicles improve oral bioavailability of poor water-soluble gefitinib. Drug Dev Ind Pharm 2022;:1-13. [PMID: 35786162 DOI: 10.1080/03639045.2022.2098316] [Reference Citation Analysis]
62 Fan H, Zhang J, Zou B, He Z. The Role of CEP55 Expression in Tumor Immune Response and Prognosis of Patients with Non-small Cell lung Cancer. Arch Iran Med 2022;25:432-442. [DOI: 10.34172/aim.2022.72] [Reference Citation Analysis]
63 Icard P, Simula L, Fournel L, Leroy K, Lupo A, Damotte D, Charpentier MC, Durdux C, Loi M, Schussler O, Chassagnon G, Coquerel A, Lincet H, De Pauw V, Alifano M. The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications. Drug Resist Updat 2022;63:100852. [PMID: 35849943 DOI: 10.1016/j.drup.2022.100852] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
64 Fang C, Liang Y, Huang Y, Jiang D, Li J, Ma H, Guo L, Jiang W, Feng Y. P3H4 Promotes Malignant Progression of Lung Adenocarcinoma via Interaction with EGFR. Cancers 2022;14:3243. [DOI: 10.3390/cancers14133243] [Reference Citation Analysis]
65 Qu J, Shen Q, Li Y, Kalyani FS, Liu L, Zhou J, Zhou J. Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation. Front Oncol 2022;12:911303. [DOI: 10.3389/fonc.2022.911303] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Zhang L, Yang L, Sun B, Deng Y, Yang J, Wu D, Kong F. Case Report: Afatinib Sensitivity in Rare EGFR E746_L747delinsIP Mutated LUAD With Peritoneal Metastases. Front Oncol 2022;12:861271. [PMID: 35712479 DOI: 10.3389/fonc.2022.861271] [Reference Citation Analysis]
67 Chen S, Zhang W, Yuan D, Yu W, Ye X, Ling C. LINC00116 Is a Novel Prognostic Biomarker of Nonsmall Cell Lung Cancer. Genet Test Mol Biomarkers 2022;26:340-7. [PMID: 35763382 DOI: 10.1089/gtmb.2022.0004] [Reference Citation Analysis]
68 Huang L, Liao Z, Liu Z, Chen Y, Huang T, Xiao H. Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer. Front Pharmacol 2022;13:900825. [PMID: 35620280 DOI: 10.3389/fphar.2022.900825] [Reference Citation Analysis]
69 Sun SL, Wu SH, Kang JB, Ma YY, Chen L, Cao P, Chang L, Ding N, Xue X, Li NG, Shi ZH. Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance. J Med Chem 2022. [PMID: 35594541 DOI: 10.1021/acs.jmedchem.2c00030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
70 Simula L, Alifano M, Icard P. How Phosphofructokinase-1 Promotes PI3K and YAP/TAZ in Cancer: Therapeutic Perspectives. Cancers (Basel) 2022;14:2478. [PMID: 35626081 DOI: 10.3390/cancers14102478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Wu L, Yu Y, Xu L, Wang X, Zhou J, Wang Y. TROY Modulates Cancer Stem-Like Cell Properties and Gefitinib Resistance Through EMT Signaling in Non–Small Cell Lung Cancer. Front Genet 2022;13:881875. [DOI: 10.3389/fgene.2022.881875] [Reference Citation Analysis]
72 Zhang Y, Qiu F, Ye T, Lee SH, Xu J, Jia L, Zeng R, Wang X, Hu X, Yan X, Li H, Lu Y, Wang X, Jiang R, Xu W. Epiregulin increases stemness-associated genes expression and promotes chemoresistance of non-small cell lung cancer via ERK signaling. Stem Cell Res Ther 2022;13:197. [PMID: 35551652 DOI: 10.1186/s13287-022-02859-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Chen Z, Liu L, Zhu F, Cai X, Zhao Y, Liang P, Ou L, Zhong R, Yu Z, Li C, Li J, Xiong S, Feng Y, Cheng B, Liang H, Xie Z, Liang W, He J. Dynamic monitoring serum tumor markers to predict molecular features of EGFR-mutated lung cancer during targeted therapy. Cancer Med 2022. [PMID: 35543090 DOI: 10.1002/cam4.4676] [Reference Citation Analysis]
74 Huang J, Zhuang C, Chen J, Chen X, Li X, Zhang T, Wang B, Feng Q, Zheng X, Gong M, Gong Q, Xiao K, Luo K, Li W. Targeted Drug/Gene/Photodynamic Therapy via a Stimuli-Responsive Dendritic-Polymer-Based Nanococktail for Treatment of EGFR-TKI-Resistant Non-Small-Cell Lung Cancer. Adv Mater 2022;:e2201516. [PMID: 35481881 DOI: 10.1002/adma.202201516] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
75 Kaewjanthong P, Sooksai S, Sasano H, Hutvagner G, Bajan S, McGowan E, Boonyaratanakornkit V. Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells. PLoS One 2022;17:e0264717. [PMID: 35235599 DOI: 10.1371/journal.pone.0264717] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
76 Yang X, Tao L, Xu Y, Li S, Yang W, Wang L, Zhu J. CircMYC promotes proliferation, migration, invasion and inhibits apoptosis of small cell lung cancer by targeting miR-145/ Matrix Metallopeptidase 2 axis. Bioengineered 2022;13:10552-63. [PMID: 35441564 DOI: 10.1080/21655979.2022.2062978] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Yang Y, Yang X, Wang Y, Xu J, Shen H, Gou H, Qin X, Jiang G. Combined Consideration of Tumor-Associated Immune Cell Density and Immune Checkpoint Expression in the Peritumoral Microenvironment for Prognostic Stratification of Non-Small-Cell Lung Cancer Patients. Front Immunol 2022;13:811007. [PMID: 35222387 DOI: 10.3389/fimmu.2022.811007] [Reference Citation Analysis]
78 Zhou Y, Song L, Xu Q, Zeng L, Jiang W, Yang N, Zhang Y. Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib. Lung Cancer 2022;167:58-64. [PMID: 35405360 DOI: 10.1016/j.lungcan.2022.04.002] [Reference Citation Analysis]
79 Wang J, Liu X, Huang Y, Li P, Yang M, Zeng S, Chen D, Wang Q, Liu H, Luo K, Deng J. Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells. Cell Death Discov 2022;8:170. [PMID: 35387964 DOI: 10.1038/s41420-022-00966-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Zhu L, Ye D, Lei T, Wu J, Wang W, Xu B. Cancer mutation profiles predict ICIs efficacy in patients with non-small cell lung cancer. Expert Rev Mol Med 2022;24:e16. [PMID: 35373730 DOI: 10.1017/erm.2022.9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Steeghs EM, Groen HJ, Schuuring E, Aarts MJ, Damhuis RA, Voorham QJ, consortium P, Ligtenberg MJ, Grünberg K. Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.04.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
82 Lv M, Hu W, Zhang S, He L, Hu C, Yang S. Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215716] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
83 Ren C, Li J, Zhou Y, Zhang S, Wang Q. Typical tumor immune microenvironment status determine prognosis in lung adenocarcinoma. Translational Oncology 2022;18:101367. [DOI: 10.1016/j.tranon.2022.101367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
84 Sochacka-Ćwikła A, Mączyński M, Regiec A. FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. Molecules 2022;27:2259. [PMID: 35408658 DOI: 10.3390/molecules27072259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
85 Branco H, Oliveira J, Antunes C, Santos LL, Vasconcelos MH, Xavier CPR. Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin. Int J Mol Sci 2022;23. [PMID: 35408988 DOI: 10.3390/ijms23073631] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
86 Hou Z, Meng C, Yang F, Deng Y, Han X, Liu H. Mapping Tyrosine Kinases Based on a TK Activity-Representing Peptide Library Reveals a Role for SRC in H1975 Drug Resistance. J Proteome Res 2022. [PMID: 35293747 DOI: 10.1021/acs.jproteome.1c00980] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
87 Radhakrishnan D, Mohanan S, Choi G, Choy J, Tiburcius S, Trinh HT, Bolan S, Verrills N, Tanwar P, Karakoti A, Vinu A. The emergence of nanoporous materials in lung cancer therapy. Science and Technology of Advanced Materials. [DOI: 10.1080/14686996.2022.2052181] [Reference Citation Analysis]
88 Thavornpradit S, Usama SM, Park GK, Dinh J, Choi HS, Burgess K. QuatCy-I2 and MHI-I2 in Photodynamic Therapy. ACS Med Chem Lett 2022;13:470-4. [PMID: 35300076 DOI: 10.1021/acsmedchemlett.1c00640] [Reference Citation Analysis]
89 Yan L, Wang Q, Liu L, Le Y. Design, synthesis and biological evaluation of a series of dianilinopyrimidines as EGFR inhibitors. J Enzyme Inhib Med Chem 2022;37:832-43. [PMID: 35260020 DOI: 10.1080/14756366.2022.2046567] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
90 Li X, Jin L, Yuchao M, Jiang Z, Tang H, Tong X. Xanthohumol inhibits non-small cell lung cancer by activating PUMA-mediated apoptosis. Toxicology 2022. [DOI: 10.1016/j.tox.2022.153141] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
91 Bäumer N, Tiemann J, Scheller A, Meyer T, Wittmann L, Suburu MEG, Greune L, Peipp M, Kellmann N, Gumnior A, Brand C, Hartmann W, Rossig C, Müller-tidow C, Neri D, Strassert CA, Rüter C, Dersch P, Lenz G, Koeffler HP, Berdel WE, Bäumer S. Targeted siRNA nanocarrier: a platform technology for cancer treatment. Oncogene. [DOI: 10.1038/s41388-022-02241-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Li L, Zhang H, Xie Y, Su N, Su S, Zhang X, Cen W, Koundal D. The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study. Computational and Mathematical Methods in Medicine 2022;2022:1-6. [DOI: 10.1155/2022/1475871] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Shi Y, Xu Y, Xu Z, Wang H, Zhang J, Wu Y, Tang B, Zheng S, Wang K. TKI resistant-based prognostic immune related gene signature in LUAD, in which FSCN1 contributes to tumor progression. Cancer Lett 2022;:215583. [PMID: 35149175 DOI: 10.1016/j.canlet.2022.215583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
94 Zhang C, Xie H, Zhang Z, Wen B, Cao H, Bai Y, Che Q, Guo J, Su Z. Applications and Biocompatibility of Mesoporous Silica Nanocarriers in the Field of Medicine. Front Pharmacol 2022;13:829796. [DOI: 10.3389/fphar.2022.829796] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Qu J, Yan H, Hou Y, Cao W, Liu Y, Zhang E, He J, Cai Z. RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential. J Hematol Oncol 2022;15. [DOI: 10.1186/s13045-022-01224-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
96 Jia Q, Liao X, Zhang Y, Xu B, Song Y, Bian G, Fu X. Anti-Tumor Role of CAMK2B in Remodeling the Stromal Microenvironment and Inhibiting Proliferation in Papillary Renal Cell Carcinoma. Front Oncol 2022;12:740051. [DOI: 10.3389/fonc.2022.740051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
97 Ji J, Xie M, Qian Q, Xu Y, Shi W, Chen Z, Ren D, Liu W, He X, Lv M, Ma J, Liu W, Li A, Liu B. SOX9-mediated UGT8 expression promotes glycolysis and maintains the malignancy of non-small cell lung cancer. Biochem Biophys Res Commun 2022;587:139-45. [PMID: 34872002 DOI: 10.1016/j.bbrc.2021.11.099] [Reference Citation Analysis]
98 Chen Z, Tang WJ, Zhou YH, Chen ZM, Liu K. Andrographolide inhibits non-small cell lung cancer cell proliferation through the activation of the mitochondrial apoptosis pathway and by reprogramming host glucose metabolism. Ann Transl Med 2021;9:1701. [PMID: 34988210 DOI: 10.21037/atm-21-5975] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
99 Li P, Li L, Li Z, Wang S, Li R, Zhao W, Feng Y, Huang S, Li L, Qiu H, Xia S. Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway. Cancer Cell Int 2022;22:7. [PMID: 34991599 DOI: 10.1186/s12935-021-02427-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
100 Gao M, Qi Z, Feng W, Huang H, Xu Z, Dong Z, Xu M, Han J, Kloeber JA, Huang J, Lou Z, Liu S. m6A demethylation of cytidine deaminase APOBEC3B mRNA orchestrates arsenic-induced mutagenesis. J Biol Chem 2022;298:101563. [PMID: 34998823 DOI: 10.1016/j.jbc.2022.101563] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
101 Zhu J, Mou Y, Ye S, Hu H, Wang R, Yang Q, Hu Y. Identification of a Six-Gene SLC Family Signature With Prognostic Value in Patients With Lung Adenocarcinoma. Front Cell Dev Biol 2021;9:803198. [PMID: 34977043 DOI: 10.3389/fcell.2021.803198] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Lee R, Girard N, Popat S. Molecular Targetable Pathways – EGFR. Encyclopedia of Respiratory Medicine 2022. [DOI: 10.1016/b978-0-08-102723-3.00146-3] [Reference Citation Analysis]
103 Ng K, Main K, Forster M. Molecular Targetable Pathways and Therapy—ROS1. Encyclopedia of Respiratory Medicine 2022. [DOI: 10.1016/b978-0-12-801238-3.11702-7] [Reference Citation Analysis]
104 Coakley M, Popat S. Molecular Targetable Pathways—ALK. Encyclopedia of Respiratory Medicine 2022. [DOI: 10.1016/b978-0-12-801238-3.11701-5] [Reference Citation Analysis]
105 Davies A, Forster M. Management of Advanced Disease in NSCLC. Encyclopedia of Respiratory Medicine 2022. [DOI: 10.1016/b978-0-08-102723-3.00265-1] [Reference Citation Analysis]
106 申 越. Research Progress on Small Molecules Targeted Therapy in Non-Small Cell Lung Cancer. WJCR 2022;12:90-98. [DOI: 10.12677/wjcr.2022.122012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
107 Wen Q, Zhang Y, Muluh TA, Xiong K, Wang B, Lu Y, Wu Z, Liu Y, Shi H, Xiao S, Fu S. Erythrocyte membrane-camouflaged gefitinib/albumin nanoparticles for tumor imaging and targeted therapy against lung cancer. Int J Biol Macromol 2021;193:228-37. [PMID: 34688683 DOI: 10.1016/j.ijbiomac.2021.10.113] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
108 Zheng Y, Tang L, Liu Z. Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer. BMC Cancer 2021;21:1322. [PMID: 34893051 DOI: 10.1186/s12885-021-09044-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
109 Yang CZ, Hu LH, Huang ZY, Deng L, Guo W, Liu S, Xiao X, Yang HX, Lin JT, Sun LL, Lin LZ. Comprehensive analysis of an immune infiltrate-related competitive endogenous RNA network reveals potential prognostic biomarkers for non-small cell lung cancer. PLoS One 2021;16:e0260720. [PMID: 34855841 DOI: 10.1371/journal.pone.0260720] [Reference Citation Analysis]
110 Zhu F, Xu L, Li X, Li Z, Wang J, Chen H, Li X, Gao Y. Co-delivery of gefitinib and hematoporphyrin by aptamer-modified fluorinated dendrimer for hypoxia alleviation and enhanced synergistic chemo-photodynamic therapy of NSCLC. Eur J Pharm Sci 2021;167:106004. [PMID: 34520834 DOI: 10.1016/j.ejps.2021.106004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
111 Gong K, Guo G, Beckley NA, Yang X, Zhang Y, Gerber DE, Minna JD, Burma S, Zhao D, Akbay EA, Habib AA. Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids. Nat Commun 2021;12:7014. [PMID: 34853306 DOI: 10.1038/s41467-021-27276-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
112 Zhang H, Zhang L, Gao C, Yu R, Kang C. Pharmacophore screening, molecular docking, ADMET prediction and MD simulations for identification of ALK and MEK potential dual inhibitors. Journal of Molecular Structure 2021;1245:131066. [DOI: 10.1016/j.molstruc.2021.131066] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
113 Zhou D, Gulinuer W, Zhu N. Chemotherapy in combination with pembrolizumab and antiangiogenesis in young patients with advanced primary pulmonary mucinous adenocarcinoma: Two case reports. Sci Prog 2021;104:368504211061971. [PMID: 34842490 DOI: 10.1177/00368504211061971] [Reference Citation Analysis]
114 Ntzifa A, Londra D, Rampias T, Kotsakis A, Georgoulias V, Lianidou E. DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment. Cancers (Basel) 2021;13:5974. [PMID: 34885084 DOI: 10.3390/cancers13235974] [Reference Citation Analysis]
115 Zhang Q, Jia H, Wang Z, Hao S, Huang H, Yang A, Han L, Song P. Intertumoural Heterogeneity and Branch Evolution of Synchronous Multiple Primary Lung Adenocarcinomas by Next-Generation Sequencing Analysis. Front Oncol 2021;11:760715. [PMID: 34804960 DOI: 10.3389/fonc.2021.760715] [Reference Citation Analysis]
116 Zhu X, Zhou R, Lu Y, Zhang Y, Chen Q, Li Y. Identification and Validation of Afatinib Potential Drug Resistance Gene BIRC5 in Non-Small Cell Lung Cancer. Front Oncol 2021;11:763035. [PMID: 34804966 DOI: 10.3389/fonc.2021.763035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
117 Fukuda N, Horita N, Namkoong H, Kaneko A, Somekawa K, Tagami Y, Watanabe K, Hara Y, Kobayashi N, Kaneko T. Best regimens for treating chemo-naïve incurable squamous non-small cell lung cancer with a programmed death-ligand 1 tumor proportion score of 1%-49%: A network meta-analysis. Thorac Cancer 2021. [PMID: 34791815 DOI: 10.1111/1759-7714.14229] [Reference Citation Analysis]
118 Zhang S, Dai H, Li W, Wang R, Wu H, Shen M, Hu Y, Xie L, Xing Y. TMEM116 is required for lung cancer cell motility and metastasis through PDK1 signaling pathway. Cell Death Dis 2021;12:1086. [PMID: 34789718 DOI: 10.1038/s41419-021-04369-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
119 Liu J, Xue L, Xu X, Luo J, Zhang S. FAK-targeting PROTAC demonstrates enhanced antitumor activity against KRAS mutant non-small cell lung cancer. Exp Cell Res 2021;408:112868. [PMID: 34648846 DOI: 10.1016/j.yexcr.2021.112868] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
120 Leiser D, Samanta S, Eley J, Strauss J, Creed M, Kingsbury T, Staats PN, Bhandary B, Chen M, Dukic T, Roy S, Mahmood J, Vujaskovic Z, Shukla HD. Role of caveolin-1 as a biomarker for radiation resistance and tumor aggression in lung cancer. PLoS One 2021;16:e0258951. [PMID: 34762666 DOI: 10.1371/journal.pone.0258951] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
121 Yan D, Earp HS, DeRyckere D, Graham DK. Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer. Cancers (Basel) 2021;13:5639. [PMID: 34830794 DOI: 10.3390/cancers13225639] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
122 Ando T, Arang N, Wang Z, Costea DE, Feng X, Goto Y, Izumi H, Gilardi M, Ando K, Gutkind JS. EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1. Commun Biol 2021;4:1237. [PMID: 34725466 DOI: 10.1038/s42003-021-02744-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
123 Xia Y, Wang WC, Shen WH, Xu K, Hu YY, Han GH, Liu YB. Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC. Chem Biol Interact 2021;349:109652. [PMID: 34520751 DOI: 10.1016/j.cbi.2021.109652] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
124 Zhang L, Peng H, Xu Z, Yang Q, Wang Y, Wang H, Bu L. Circular RNA SOX13 promotes malignant behavior and cisplatin resistance in non-small cell lung cancer through targeting microRNA-3194-3p/microtubule-associated protein RP/EB family member 1. Bioengineered 2021. [PMID: 34709968 DOI: 10.1080/21655979.2021.1997223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
125 Šutić M, Vukić A, Baranašić J, Försti A, Džubur F, Samaržija M, Jakopović M, Brčić L, Knežević J. Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management. J Pers Med 2021;11:1102. [PMID: 34834454 DOI: 10.3390/jpm11111102] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
126 Jing X, Niu S, Liang Y, Chen H, Wang N, Peng Y, Ma F, Yue W, Wang Q, Chang J, Zhang Y, Zhang Y. FNC inhibits non-small cell lung cancer by activating the mitochondrial apoptosis pathway. Genes Genomics 2021. [PMID: 34697761 DOI: 10.1007/s13258-021-01179-9] [Reference Citation Analysis]
127 Esposito R, Polidori T, Meise DF, Pulido-quetglas C, Chouvardas P, Forster S, Schaerer P, Kobel A, Schlatter J, Roemmele M, Westemeier ES, Zhu L, Lanzós A, Guillen-ramirez HA, Basile G, Carrozzo I, Vancura A, Ullrich S, Andrades A, Harvey D, Medina PP, Ma PC, Haefliger S, Wang X, Martinez I, Ochsenbein A, Riether C, Johnson R. Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities.. [DOI: 10.1101/2021.10.19.464956] [Reference Citation Analysis]
128 Xu Y, Hu Y, Xu T, Yan K, Zhang T, Li Q, Chang F, Guo X, Peng J, Li M, Zhao M, Zhen H, Xu L, Zheng D, Li L, Shao G. RNF8-mediated regulation of Akt promotes lung cancer cell survival and resistance to DNA damage. Cell Rep 2021;37:109854. [PMID: 34686341 DOI: 10.1016/j.celrep.2021.109854] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
129 Zhao Y, Wang H, He C. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy. J Cancer Res Clin Oncol 2021;147:3653-64. [PMID: 34661758 DOI: 10.1007/s00432-021-03828-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
130 Li K, Peng ZY, Gao S, Wang QS, Wang R, Li X, Xiao GD, Zhang J, Ren H, Tang SC, Sun X. M6A associated TSUC7 inhibition contributed to Erlotinib resistance in lung adenocarcinoma through a notch signaling activation dependent way. J Exp Clin Cancer Res 2021;40:325. [PMID: 34656164 DOI: 10.1186/s13046-021-02137-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
131 Xu L, Chen X, Huo H, Liu Y, Yang X, Gu D, Yuan M, Zhang M, Chen R, Wang J, Zheng Z. Case Report: Detection of Double ROS1 Translocations, SDC4-ROS1 and ROS1-GK, in a Lung Adenocarcinoma Patient and Response to Crizotinib. Front Med (Lausanne) 2021;8:649177. [PMID: 34616749 DOI: 10.3389/fmed.2021.649177] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
132 Zhang KR, Zhang YF, Lei HM, Tang YB, Ma CS, Lv QM, Wang SY, Lu LM, Shen Y, Chen HZ, Zhu L. Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer. Sci Transl Med 2021;13:eabg6428. [PMID: 34613810 DOI: 10.1126/scitranslmed.abg6428] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
133 Serna-Blasco R, Sánchez-Herrero E, Sanz-Moreno S, Rodriguez-Festa A, García-Veros E, Casarrubios M, Sierra-Rodero B, Laza-Briviesca R, Cruz-Bermúdez A, Mielgo-Rubio X, Sánchez-Hernández A, Uribelarrea EA, Calvo V, Romero A, Provencio M. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor. ESMO Open 2021;6:100279. [PMID: 34607284 DOI: 10.1016/j.esmoop.2021.100279] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
134 Dai J, Jiang M, He K, Wang H, Chen P, Guo H, Zhao W, Lu H, He Y, Zhou C. DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer. Front Oncol 2021;11:708294. [PMID: 34604048 DOI: 10.3389/fonc.2021.708294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
135 Jiang Y, Zhuo X, Wu Y, Fu X, Mao C. PAR2 blockade reverses osimertinib resistance in non-small-cell lung cancer cells via attenuating ERK-mediated EMT and PD-L1 expression. Biochim Biophys Acta Mol Cell Res 2022;1869:119144. [PMID: 34599981 DOI: 10.1016/j.bbamcr.2021.119144] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
136 Wang B, Guo H, Xu H, Yu H, Chen Y, Zhao G. Research Progress and Challenges in the Treatment of Central Nervous System Metastasis of Non-Small Cell Lung Cancer. Cells 2021;10:2620. [PMID: 34685600 DOI: 10.3390/cells10102620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
137 Fukuda N, Horita N, Katakura S, Namkoong H, Kaneko A, Somekawa K, Tagami Y, Watanabe K, Hara Y, Kobayashi N, Kaneko T. The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1-49%: a network meta-analysis. Transl Lung Cancer Res 2021;10:3550-66. [PMID: 34584856 DOI: 10.21037/tlcr-21-419] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
138 Kaczmarczyk JA, Roberts RR, Luke BT, Chan KC, Van Wagoner CM, Felder RA, Saul RG, Simona C, Blonder J. Comparative microsomal proteomics of a model lung cancer cell line NCI-H23 reveals distinct differences between molecular profiles of 3D and 2D cultured cells. Oncotarget 2021;12:2022-38. [PMID: 34611477 DOI: 10.18632/oncotarget.28072] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
139 Wu CP, Li YQ, Hung TH, Chang YT, Huang YH, Wu YS. Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs. J Nat Prod 2021;84:2544-53. [PMID: 34496204 DOI: 10.1021/acs.jnatprod.1c00584] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
140 Hijazo-Pechero S, Alay A, Marín R, Vilariño N, Muñoz-Pinedo C, Villanueva A, Santamaría D, Nadal E, Solé X. Gene Expression Profiling as a Potential Tool for Precision Oncology in Non-Small Cell Lung Cancer. Cancers (Basel) 2021;13:4734. [PMID: 34638221 DOI: 10.3390/cancers13194734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
141 Boudy AS, Grausz N, Selleret L, Gligorov J, Thomassin-Naggara I, Touboul C, Daraï E, Cadranel J. Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma. Lung Cancer 2021;161:68-75. [PMID: 34543940 DOI: 10.1016/j.lungcan.2021.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
142 Chen SY, Zhang GC, Shu QJ. Yang-Yin-Jie-Du decoction overcomes gefitinib resistance in non-small cell lung cancer via down-regulation of the PI3K/Akt signalling pathway. Pharm Biol 2021;59:1294-304. [PMID: 34543169 DOI: 10.1080/13880209.2021.1972122] [Reference Citation Analysis]
143 Morelli AP, Tortelli TC Jr, Mancini MCS, Pavan ICB, Silva LGS, Severino MB, Granato DC, Pestana NF, Ponte LGS, Peruca GF, Pauletti BA, Dos Santos DFG Jr, de Moura LP, Bezerra RMN, Leme AFP, Chammas R, Simabuco FM. STAT3 contributes to cisplatin resistance, modulating EMT markers, and the mTOR signaling in lung adenocarcinoma. Neoplasia 2021;23:1048-58. [PMID: 34543857 DOI: 10.1016/j.neo.2021.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
144 Meng H, Huang L, Wang J, Zhou Y, Wang M, Yang Z, Hong X. Clinical outcomes of patients taking first-generation EGFR-TKIs may predict the benefits afforded by osimertinib in EGFR T790M-mutant NSCLC patients. Int J Clin Pract 2021;:e14877. [PMID: 34525256 DOI: 10.1111/ijcp.14877] [Reference Citation Analysis]
145 Zhang C, Cao H, Cui Y, Jin S, Gao W, Huang C, Guo R. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer. Thorac Cancer 2021;12:2574-84. [PMID: 34510760 DOI: 10.1111/1759-7714.14141] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
146 Wang Q. Building Personalized Cancer Therapeutics through Multi-Omics Assays and Bacteriophage-Eukaryotic Cell Interactions. Int J Mol Sci 2021;22:9712. [PMID: 34575870 DOI: 10.3390/ijms22189712] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
147 Cadranel J, Fallet V, Baldacci S, Cortot A. Algorithme thérapeutique des cancers bronchiques non à petites cellules étendus avec mutation de l’EGR. Revue des Maladies Respiratoires Actualités 2021;13:2S135-2S154. [DOI: 10.1016/s1877-1203(21)00106-3] [Reference Citation Analysis]
148 Li N, Liu M, Cao X, Li W, Li Y, Zhao Z. Identification of differentially expressed genes using microarray analysis and COL6A1 induction of bone metastasis in non-small cell lung cancer. Oncol Lett 2021;22:693. [PMID: 34457048 DOI: 10.3892/ol.2021.12954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
149 Cassidy T, Nichol D, Robertson-Tessi M, Craig M, Anderson ARA. The role of memory in non-genetic inheritance and its impact on cancer treatment resistance. PLoS Comput Biol 2021;17:e1009348. [PMID: 34460809 DOI: 10.1371/journal.pcbi.1009348] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
150 Zhu J, Ao H, Liu M, Cao K, Ma J. UBE2T promotes autophagy via the p53/AMPK/mTOR signaling pathway in lung adenocarcinoma. J Transl Med 2021;19:374. [PMID: 34461934 DOI: 10.1186/s12967-021-03056-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
151 Lan B, Wang Y, Wu J, Wang K, Wang P. The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC: A meta-analysis. Medicine (Baltimore) 2021;100:e27038. [PMID: 34449486 DOI: 10.1097/MD.0000000000027038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Belluomini L, Dodi A, Caldart A, Kadrija D, Sposito M, Casali M, Sartori G, Ferrara MG, Avancini A, Bria E, Menis J, Milella M, Pilotto S. A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done. Transl Lung Cancer Res 2021;10:3369-84. [PMID: 34430373 DOI: 10.21037/tlcr-20-1134] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
153 DE Carlo E, Schiappacassi M, Pelizzari G, Baresic T, Del Conte A, Stanzione B, DA Ros V, Doliana R, Baldassarre G, Bearz A. Acquired EGFR C797G Mutation Detected by Liquid Biopsy as Resistance Mechanism After Treatment With Osimertinib: A Case Report. In Vivo 2021;35:2941-5. [PMID: 34410991 DOI: 10.21873/invivo.12586] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
154 Molavipordanjani S, Hosseinimehr SJ. The Radiolabeled HER3 Targeting Molecules for Tumor Imaging. Iran J Pharm Res 2021;20:141-52. [PMID: 34400948 DOI: 10.22037/ijpr.2021.114677.14991] [Reference Citation Analysis]
155 Nguyen HN, Cao NT, Van Nguyen TC, Le KND, Nguyen DT, Nguyen QT, Nguyen TT, Van Nguyen C, Le HT, Nguyen MT, Nguyen TV, Tran VU, Luong BA, Le LGH, Ho QC, Pham HT, Vo BT, Nguyen LT, Dang AH, Nguyen SD, Do DM, Do TT, Hoang AV, Dinh KT, Phan MD, Giang H, Tran LS. Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in NSCLC patients with different EGFR-TKI resistant mutations. Sci Rep 2021;11:16436. [PMID: 34385540 DOI: 10.1038/s41598-021-95985-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
156 Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med 2021;27:1345-56. [PMID: 34385702 DOI: 10.1038/s41591-021-01450-2] [Cited by in Crossref: 73] [Cited by in F6Publishing: 81] [Article Influence: 36.5] [Reference Citation Analysis]
157 Vichas A, Riley AK, Nkinsi NT, Kamlapurkar S, Parrish PCR, Lo A, Duke F, Chen J, Fung I, Watson J, Rees M, Gabel AM, Thomas JD, Bradley RK, Lee JK, Hatch EM, Baine MK, Rekhtman N, Ladanyi M, Piccioni F, Berger AH. Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer. Nat Commun 2021;12:4789. [PMID: 34373451 DOI: 10.1038/s41467-021-24841-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
158 Rosell R, Cardona AF, Arrieta O, Aguilar A, Ito M, Pedraz C, Codony-Servat J, Santarpia M. Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities. Br J Cancer 2021. [PMID: 34373568 DOI: 10.1038/s41416-021-01519-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
159 Liu J, Shi X, Zhang R, Zhang M, He J, Chen J, Wang Z, Wang Q. CoFe2O4-Quantum Dots for Synergistic Photothermal/Photodynamic Therapy of Non-small-Cell Lung Cancer Via Triggering Apoptosis by Regulating PI3K/AKT Pathway. Nanoscale Res Lett 2021;16:120. [PMID: 34322770 DOI: 10.1186/s11671-021-03580-5] [Reference Citation Analysis]
160 Yang M, Yang F, Chen W, Liu S, Qiu L, Chen J. Bacteria-mediated cancer therapies: opportunities and challenges. Biomater Sci 2021;9:5732-44. [PMID: 34313267 DOI: 10.1039/d1bm00634g] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
161 Tanaka K, Yu HA, Yang S, Han S, Selcuklu SD, Kim K, Ramani S, Ganesan YT, Moyer A, Sinha S, Xie Y, Ishizawa K, Osmanbeyoglu HU, Lyu Y, Roper N, Guha U, Rudin CM, Kris MG, Hsieh JJ, Cheng EH. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell 2021:S1535-6108(21)00383-4. [PMID: 34388376 DOI: 10.1016/j.ccell.2021.07.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
162 Yang Z, Li G, Zhao Y, Zhang L, Yuan X, Meng L, Liu H, Han Y, Jia L, Zhang S. Molecular Insights into the Recruiting Between UCP2 and DDX5/UBAP2L in the Metabolic Plasticity of Non-Small-Cell Lung Cancer. J Chem Inf Model 2021;61:3978-87. [PMID: 34308648 DOI: 10.1021/acs.jcim.1c00138] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
163 Gong L, Shu J, Chen X, Pan H, Chen G, Bi Y, Cui D, Li X, Liu D, Wang L, Wang Y, Liu P, Xiong X, Zhao Y. DEPTOR inhibits lung tumorigenesis by inactivating the EGFR-mTOR signals. Cancer Lett 2021;519:263-76. [PMID: 34320372 DOI: 10.1016/j.canlet.2021.07.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
164 Min W, He C, Zhang S, Zhao Y. c-Src Increases the Sensitivity to TKIs in the EGFR-Mutant Lung Adenocarcinoma. Front Oncol 2021;11:602900. [PMID: 34367939 DOI: 10.3389/fonc.2021.602900] [Reference Citation Analysis]
165 Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet 2021;398:535-54. [PMID: 34273294 DOI: 10.1016/S0140-6736(21)00312-3] [Cited by in Crossref: 193] [Cited by in F6Publishing: 258] [Article Influence: 96.5] [Reference Citation Analysis]
166 Oulhen M, Pawlikowska P, Tayoun T, Garonzi M, Buson G, Forcato C, Manaresi N, Aberlenc A, Mezquita L, Lecluse Y, Lavaud P, Naltet C, Planchard D, Besse B, Farace F. Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. NPJ Precis Oncol 2021;5:67. [PMID: 34272470 DOI: 10.1038/s41698-021-00203-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
167 Fang Y, Wang Y, Zeng D, Zhi S, Shu T, Huang N, Zheng S, Wu J, Liu Y, Huang G, Xue Y, Bin J, Liao Y, Shi M, Liao W. Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer. Oncoimmunology 2021;10:1951019. [PMID: 34345533 DOI: 10.1080/2162402X.2021.1951019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
168 Wang H, Si S, Jiang M, Chen L, Huang K, Yu W. Leukemia inhibitory factor is involved in the pathogenesis of NSCLC through activation of the STAT3 signaling pathway. Oncol Lett 2021;22:663. [PMID: 34386085 DOI: 10.3892/ol.2021.12924] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
169 Crintea A, Dutu AG, Samasca G, Florian IA, Lupan I, Craciun AM. The Nanosystems Involved in Treating Lung Cancer. Life (Basel) 2021;11:682. [PMID: 34357054 DOI: 10.3390/life11070682] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
170 Fu W, Zhao J, Hu W, Dai L, Jiang Z, Zhong S, Deng B, Huang Y, Wu W, Yin J. LINC01224/ZNF91 Promote Stem Cell-Like Properties and Drive Radioresistance in Non-Small Cell Lung Cancer. Cancer Manag Res 2021;13:5671-81. [PMID: 34285587 DOI: 10.2147/CMAR.S313744] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
171 Chen HH, Zhang TN, Wu QJ, Huang XM, Zhao YH. Circular RNAs in Lung Cancer: Recent Advances and Future Perspectives. Front Oncol 2021;11:664290. [PMID: 34295810 DOI: 10.3389/fonc.2021.664290] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
172 Yong J, Huang L, Chen G, Luo X, Chen H, Wang L. High expression of Stabilin-2 predicts poor prognosis in non-small-cell lung cancer. Bioengineered 2021;12:3426-33. [PMID: 34227915 DOI: 10.1080/21655979.2021.1943109] [Reference Citation Analysis]
173 Zheng Y, Yao M, Yang Y. Higher Tumor Mutation Burden Was a Predictor for Better Outcome for NSCLC Patients Treated with PD-1 Antibodies: A Systematic Review and Meta-analysis. SLAS Technol 2021;:24726303211024557. [PMID: 34180302 DOI: 10.1177/24726303211024557] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
174 Li Y, Ma Y, Zhang T, Feng C, Liu Y. High-mobility group box 3 (HMGB3) silencing inhibits non-small cell lung cancer development through regulating Wnt/β-catenin pathway. Biol Chem 2020;401:1191-8. [PMID: 32386184 DOI: 10.1515/hsz-2020-0144] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
175 Icard P, Coquerel A, Wu Z, Gligorov J, Fuks D, Fournel L, Lincet H, Simula L. Understanding the Central Role of Citrate in the Metabolism of Cancer Cells and Tumors: An Update. Int J Mol Sci 2021;22:6587. [PMID: 34205414 DOI: 10.3390/ijms22126587] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
176 Gao L, Wu ZX, Assaraf YG, Chen ZS, Wang L. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resist Updat 2021;57:100770. [PMID: 34175687 DOI: 10.1016/j.drup.2021.100770] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
177 Mughal MJ, Kwok HF. Multidimensional role of bacteria in cancer: Mechanisms insight, diagnostic, preventive and therapeutic potential. Semin Cancer Biol 2021:S1044-579X(21)00181-4. [PMID: 34119644 DOI: 10.1016/j.semcancer.2021.06.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
178 Li M, Wang Q, Zhang X, Yan N, Li X. CircPUM1 promotes cell growth and glycolysis in NSCLC via up-regulating METTL3 expression through miR-590-5p. Cell Cycle 2021;20:1279-94. [PMID: 34097560 DOI: 10.1080/15384101.2021.1934625] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
179 Pan S, Zhang Y, Huang M, Deng Z, Zhang A, Pei L, Wang L, Zhao W, Ma L, Zhang Q, Cui D. Urinary exosomes-based Engineered Nanovectors for Homologously Targeted Chemo-Chemodynamic Prostate Cancer Therapy via abrogating EGFR/AKT/NF-kB/IkB signaling. Biomaterials 2021;275:120946. [PMID: 34119884 DOI: 10.1016/j.biomaterials.2021.120946] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 16.0] [Reference Citation Analysis]
180 Wang X, Cheng Z, Dai L, Jiang T, Li P, Jia L, Jing X, An L, Liu M, Wu S, Wang Y. LncRNA PVT1 Facilitates Proliferation, Migration and Invasion of NSCLC Cells via miR-551b/FGFR1 Axis. Onco Targets Ther 2021;14:3555-65. [PMID: 34113122 DOI: 10.2147/OTT.S273794] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
181 Xia ZJ, Ji YC, Sun DQ, Peng X, Gao YL, Fang YF, Zhao XD, Wang WB, Ding J, Geng MY, Ai J. SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors. Acta Pharmacol Sin 2021;42:998-1004. [PMID: 32918045 DOI: 10.1038/s41401-020-00513-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
182 Cai X, Miao J, Sun R, Wang S, Molina-Vila MA, Chaib I, Rosell R, Cao P. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer. Pharmacol Res 2021;170:105701. [PMID: 34087353 DOI: 10.1016/j.phrs.2021.105701] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
183 Wang J, Song Y, Zhang N, Li N, Liu C, Wang B. Using Liposomes to Alleviate the Toxicity of Chelerythrine, a Natural PKC Inhibitor, in Treating Non-Small Cell Lung Cancer. Front Oncol 2021;11:658543. [PMID: 34123813 DOI: 10.3389/fonc.2021.658543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
184 Xie G, Li Y, Jiang Y, Ye X, Tang J, Chen J. Silencing HIPPI Suppresses Tumor Progression in Non-Small-Cell Lung Cancer by Inhibiting DNA Replication. Onco Targets Ther 2021;14:3467-80. [PMID: 34079292 DOI: 10.2147/OTT.S305388] [Reference Citation Analysis]
185 Ma J, Miao H, Zhang H, Ren J, Qu S, Da J, Xu F, Zhao H. LncRNA GAS5 modulates the progression of non-small cell lung cancer through repressing miR-221-3p and up-regulating IRF2. Diagn Pathol 2021;16:46. [PMID: 34022918 DOI: 10.1186/s13000-021-01108-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
186 Zhao D, Chen J, Wang Y, Zhang L, Zhang J, Zhang W, Fan J, Li J, Zhan Q. Feed-forward activation of STAT3 signaling limits the efficacy of c-Met inhibitors in esophageal squamous cell carcinoma (ESCC) treatment. Mol Carcinog 2021;60:481-96. [PMID: 34018249 DOI: 10.1002/mc.23306] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
187 Luo R, Ge C, Xiao X, Song J, Miao S, Tang Y, Lai J, Nian W, Song F, Ran L. Identification of genetic variations associated with drug resistance in non-small cell lung cancer patients undergoing systemic treatment. Brief Bioinform 2021:bbab187. [PMID: 34013324 DOI: 10.1093/bib/bbab187] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
188 Deneka AY, Kopp MC, Nikonova AS, Gaponova AV, Kiseleva AA, Hensley HH, Flieder DB, Serebriiskii IG, Golemis EA. Nedd9 Restrains Autophagy to Limit Growth of Early Stage Non-Small Cell Lung Cancer. Cancer Res 2021;81:3717-26. [PMID: 34006524 DOI: 10.1158/0008-5472.CAN-20-3626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
189 Qiu Y, Yin X, Li X, Wang Y, Fu Q, Huang R, Lu S. Untangling Dual-Targeting Therapeutic Mechanism of Epidermal Growth Factor Receptor (EGFR) Based on Reversed Allosteric Communication. Pharmaceutics 2021;13:747. [PMID: 34070173 DOI: 10.3390/pharmaceutics13050747] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
190 Liu Y, Ge X, Pang J, Zhang Y, Zhang H, Wu H, Fan F, Liu H. Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib. Front Pharmacol 2021;12:671328. [PMID: 34054543 DOI: 10.3389/fphar.2021.671328] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
191 Bronte G, Cafaro A, Pasini L, Priano I, Andrikou K, Cravero P, Burgio MA, Delmonte A, Crinò L. Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy. Expert Rev Anticancer Ther 2021;21:809-17. [PMID: 33905667 DOI: 10.1080/14737140.2021.1923485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
192 He Y, Chen L, Zhao L, Dang S, Liu G, Sasada S, Ma PC, van Zandwijk N, Rosell R, Popper HH, Wang H, Jiang M, Guo H, Liu X, Chen S, Zhang X, Xu M, Zhu B, Liu M, Zhou C. Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC. Theranostics 2021;11:7092-109. [PMID: 34093873 DOI: 10.7150/thno.58039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
193 Peng Z, Lin H, Zhou K, Deng S, Mei J. Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis. World J Surg Oncol 2021;19:145. [PMID: 33964931 DOI: 10.1186/s12957-021-02254-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
194 Nastase A, Lupo A, Laszlo V, Damotte D, Dima S, Canny E, Alifano M, Popescu I, Klepetko W, Grigoroiu M. Platinum Drug Sensitivity Polymorphisms in Stage III Non-small Cell Lung Cancer With Invasion of Mediastinal Lymph Nodes. Cancer Genomics Proteomics 2020;17:587-95. [PMID: 32859637 DOI: 10.21873/cgp.20215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
195 Zhang J, Li C, Zhang L, Heng Y, Xu T, Zhang Y, Chen X, Hoffman RM, Jia L. Andrographolide Induces Noxa-Dependent Apoptosis by Transactivating ATF4 in Human Lung Adenocarcinoma Cells. Front Pharmacol 2021;12:680589. [PMID: 33995110 DOI: 10.3389/fphar.2021.680589] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
196 Jiang Y, Zhuo X, Fu X, Wu Y, Mao C. Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation. Front Pharmacol 2021;12:625289. [PMID: 33967759 DOI: 10.3389/fphar.2021.625289] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
197 Yang X, Li Y, Duan Q, Zhang Q, He M. Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment. J Thorac Oncol 2021;16:e17-9. [PMID: 33641723 DOI: 10.1016/j.jtho.2020.11.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
198 Tulpule A, Guan J, Neel DS, Allegakoen HR, Lin YP, Brown D, Chou YT, Heslin A, Chatterjee N, Perati S, Menon S, Nguyen TA, Debnath J, Ramirez AD, Shi X, Yang B, Feng S, Makhija S, Huang B, Bivona TG. Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules. Cell 2021;184:2649-2664.e18. [PMID: 33848463 DOI: 10.1016/j.cell.2021.03.031] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 17.5] [Reference Citation Analysis]
199 Zewdu R, Mehrabad EM, Ingram K, Fang P, Gillis KL, Camolotto SA, Orstad G, Jones A, Mendoza MC, Spike BT, Snyder EL. An NKX2-1/ERK/WNT feedback loop modulates gastric identity and response to targeted therapy in lung adenocarcinoma. Elife 2021;10:e66788. [PMID: 33821796 DOI: 10.7554/eLife.66788] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
200 Zhao D, Fan J, Peng L, Huang B, Zhu Y, Shi H, Dai X, Nie X. Two different patterns of lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement. Tumori 2021;:3008916211005546. [PMID: 33818198 DOI: 10.1177/03008916211005546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
201 Suryavanshi M, Chaudhari K, Nathany S, Talwar V. Identification of a novel resistance ALK p.(Q1188_L1190del) deletion in a patient with ALK-rearranged non-small-cell lung cancer. Cancer Genet 2021;256-257:48-50. [PMID: 33887694 DOI: 10.1016/j.cancergen.2021.03.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
202 Liu MM, Zhu ML, Dong RF, Zhang C, Zhang H, Yang L, Kong LY, Xia YZ. Polyphyllin I promotes cell death via suppressing UPR-mediated CHOP ubiquitination and degradation in non-small cell lung cancer. Chin J Nat Med 2021;19:255-66. [PMID: 33875166 DOI: 10.1016/S1875-5364(21)60027-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
203 Chuang HH, Zhen YY, Tsai YC, Chuang CH, Huang MS, Hsiao M, Yang CJ. Targeting Pin1 for Modulation of Cell Motility and Cancer Therapy. Biomedicines 2021;9:359. [PMID: 33807199 DOI: 10.3390/biomedicines9040359] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
204 Taugner J, Käsmann L, Eze C, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F. Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting. Cancers (Basel) 2021;13:1613. [PMID: 33807324 DOI: 10.3390/cancers13071613] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
205 Lin S, Tian C, Li J, Liu B, Ma T, Chen K, Gong W, Wang JM, Huang J. Differential MUC22 expression by epigenetic alterations in human lung squamous cell carcinoma and adenocarcinoma. Oncol Rep 2021;45:78. [PMID: 33786615 DOI: 10.3892/or.2021.8029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
206 Mo DC, Huang JF, Luo PH, Huang SX, Wang HL. The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: A meta-analysis. Int Immunopharmacol 2021;96:107594. [PMID: 33798808 DOI: 10.1016/j.intimp.2021.107594] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
207 Dong RF, Zhu ML, Liu MM, Xu YT, Yuan LL, Bian J, Xia YZ, Kong LY. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research. Pharmacol Res 2021;167:105583. [PMID: 33775864 DOI: 10.1016/j.phrs.2021.105583] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
208 Zhang C, Cao J, Lv W, Mou H. CircRNA_100395 Carried by Exosomes From Adipose-Derived Mesenchymal Stem Cells Inhibits the Malignant Transformation of Non-Small Cell Lung Carcinoma Through the miR-141-3p-LATS2 Axis. Front Cell Dev Biol 2021;9:663147. [PMID: 33842488 DOI: 10.3389/fcell.2021.663147] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
209 Huo SF, Shang WL, Yu M, Ren XP, Wen HX, Chai CY, Sun L, Hui K, Liu LH, Wei SH, Wang XX, Wang Y, Tian YX. STEAP1 facilitates metastasis and epithelial-mesenchymal transition of lung adenocarcinoma via the JAK2/STAT3 signaling pathway. Biosci Rep 2020;40:BSR20193169. [PMID: 32515474 DOI: 10.1042/BSR20193169] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
210 Chen C, Hou J, Yu S, Li W, Wang X, Sun H, Qin T, Claret FX, Guo H, Liu Z. Role of cancer-associated fibroblasts in the resistance to antitumor therapy, and their potential therapeutic mechanisms in non-small cell lung cancer. Oncol Lett 2021;21:413. [PMID: 33841574 DOI: 10.3892/ol.2021.12674] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
211 Wang H, Meng D, Guo H, Sun C, Chen P, Jiang M, Xu Y, Yu J, Fang Q, Zhu J, Zhao W, Wu S, Zhao S, Li W, Chen B, Wang L, He Y. Single-Cell Sequencing, an Advanced Technology in Lung Cancer Research. Onco Targets Ther 2021;14:1895-909. [PMID: 33758510 DOI: 10.2147/OTT.S295102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
212 Aissa AF, Islam ABMMK, Ariss MM, Go CC, Rader AE, Conrardy RD, Gajda AM, Rubio-Perez C, Valyi-Nagy K, Pasquinelli M, Feldman LE, Green SJ, Lopez-Bigas N, Frolov MV, Benevolenskaya EV. Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer. Nat Commun 2021;12:1628. [PMID: 33712615 DOI: 10.1038/s41467-021-21884-z] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 19.5] [Reference Citation Analysis]
213 Ren C, Sun N, Kong Y, Qu X, Liu H, Zhong H, Song X, Yang X, Jiang B. Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib. Eur J Med Chem 2021;217:113335. [PMID: 33751979 DOI: 10.1016/j.ejmech.2021.113335] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
214 Liang L, Sun F, Wang H, Hu Z. Metabolomics, metabolic flux analysis and cancer pharmacology. Pharmacol Ther 2021;224:107827. [PMID: 33662451 DOI: 10.1016/j.pharmthera.2021.107827] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
215 Garcia J, Gauthier A, Lescuyer G, Barthelemy D, Geiguer F, Balandier J, Edelstein DL, Jones FS, Holtrup F, Duruisseau M, Grolleau E, Rodriguez-Lafrasse C, Merle P, Couraud S, Payen L. Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAMTM EGFR V2 and NGS Technologies. Mol Diagn Ther 2021;25:239-50. [PMID: 33660188 DOI: 10.1007/s40291-021-00515-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
216 Li S, Liu Y, Qiu G, Luo Y, Li X, Meng F, Li N, Xu T, Wang Y, Qin B, Xia S. Emerging roles of circular RNAs in non‑small cell lung cancer (Review). Oncol Rep 2021;45:17. [PMID: 33649862 DOI: 10.3892/or.2021.7968] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
217 Lai-kwon J, Tiu C, Pal A, Khurana S, Minchom A. Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective. Critical Reviews in Oncology/Hematology 2021;159:103225. [DOI: 10.1016/j.critrevonc.2021.103225] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
218 Wenzel C, Herold S, Saalfeld FC, Aust DE, Wermke M. The clinical benefit of molecular re-assessments in management of progressive lung cancer. Transl Lung Cancer Res 2021;10:1582-7. [PMID: 33889532 DOI: 10.21037/tlcr-20-996] [Reference Citation Analysis]
219 Lin CC, Wu CY, Tseng JT, Hung CH, Wu SY, Huang YT, Chang WY, Su PL, Su WC. Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC. Biomedicines 2021;9:243. [PMID: 33671000 DOI: 10.3390/biomedicines9030243] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
220 Domen A, Quatannens D, Zanivan S, Deben C, Van Audenaerde J, Smits E, Wouters A, Lardon F, Roeyen G, Verhoeven Y, Janssens A, Vandamme T, van Dam P, Peeters M, Prenen H. Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Cancers (Basel) 2021;13:987. [PMID: 33673405 DOI: 10.3390/cancers13050987] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
221 Garon EB, Brodrick P. Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer. Drugs 2021;81:547-54. [PMID: 33638808 DOI: 10.1007/s40265-021-01477-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
222 Dyrstad SE, Lotsberg ML, Tan TZ, Pettersen IKN, Hjellbrekke S, Tusubira D, Engelsen AST, Daubon T, Mourier A, Thiery JP, Dahl O, Lorens JB, Tronstad KJ, Røsland GV. Blocking Aerobic Glycolysis by Targeting Pyruvate Dehydrogenase Kinase in Combination with EGFR TKI and Ionizing Radiation Increases Therapeutic Effect in Non-Small Cell Lung Cancer Cells. Cancers (Basel) 2021;13:941. [PMID: 33668151 DOI: 10.3390/cancers13050941] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
223 Cassidy T, Nichol D, Robertson-tessi M, Craig M, Anderson AR. The role of memory in non-genetic inheritance and its impact on cancer treatment resistance.. [DOI: 10.1101/2021.02.22.431869] [Reference Citation Analysis]
224 Su SF, Liu CH, Cheng CL, Ho CC, Yang TY, Chen KC, Hsu KH, Tseng JS, Chen HW, Chang GC, Yu SL, Li KC. Genome-Wide Epigenetic Landscape of Lung Adenocarcinoma Links HOXB9 DNA Methylation to Intrinsic EGFR-TKI Resistance and Heterogeneous Responses. JCO Precis Oncol 2021;5:PO. [PMID: 34036228 DOI: 10.1200/PO.20.00151] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
225 Carcereny E, Fernández-Nistal A, López A, Montoto C, Naves A, Segú-Vergés C, Coma M, Jorba G, Oliva B, Mas JM. Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach. Oncotarget 2021;12:316-32. [PMID: 33659043 DOI: 10.18632/oncotarget.27875] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
226 Yu D, Zhao W, Vallega KA, Sun SY. Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling. Lung Cancer (Auckl) 2021;12:1-10. [PMID: 33574724 DOI: 10.2147/LCTT.S293902] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
227 Li W, Qian L, Li W, Chen X, He H, Tian H, Zhao Y, Wang X, Cui J. Cost-effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptor-mutated non-small-cell lung cancer. Exp Ther Med 2021;21:343. [PMID: 33732316 DOI: 10.3892/etm.2021.9774] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
228 Lou Y, Xu J, Zhang Y, Zhang W, Zhang X, Gu P, Zhong H, Wang H, Lu J, Han B. Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis. Cell Death Dis 2021;12:170. [PMID: 33568630 DOI: 10.1038/s41419-021-03439-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
229 Osarogiagbon RU, Vega DM, Fashoyin-Aje L, Wedam S, Ison G, Atienza S, De Porre P, Biswas T, Holloway JN, Hong DS, Wempe MM, Schilsky RL, Kim ES, Wade JL 3rd. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group. Clin Cancer Res 2021;27:2408-15. [PMID: 33563637 DOI: 10.1158/1078-0432.CCR-20-3854] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
230 Sinclair JKL, Robertson WE, Mozumdar D, Quach K, Schepartz A. Allosteric Inhibition of the Epidermal Growth Factor Receptor. Biochemistry 2021;60:500-12. [PMID: 33557518 DOI: 10.1021/acs.biochem.0c00978] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
231 Han X, Chen L, Hu Z, Chen L, Sun P, Wang Y, Liu Y. Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells. J Proteomics 2021;237:104122. [PMID: 33561557 DOI: 10.1016/j.jprot.2021.104122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
232 Chen CJ, Liu YP. MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. Pharmaceuticals (Basel) 2021;14:130. [PMID: 33562150 DOI: 10.3390/ph14020130] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
233 Lu Y, Yu S, Wang G, Ma Z, Fu X, Cao Y, Li Q, Xu Z. Elevation of EIF4G1 promotes non-small cell lung cancer progression by activating mTOR signalling. J Cell Mol Med 2021;25:2994-3005. [PMID: 33523588 DOI: 10.1111/jcmm.16340] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
234 N P, M V, K B, Phuong N, A P, N S. Enhanced antimicrobial, antibiofilm and anticancer activities of biocompatible neem gum coated palladium nanoparticles. Progress in Organic Coatings 2021;151:106098. [DOI: 10.1016/j.porgcoat.2020.106098] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
235 He Y, Song L, Wang H, Chen P, Liu Y, Sun H, Li X, Dang S, Liu G, Liu X, Chen S, Zhang X, Hofman P, Uchino J, Park HS, Pacheco JM, Tabbò F, Xu M, Dai J, He K, Yang Y, Zhou C; written on behalf of the AME Lung Cancer Collaborative Group. Mutational Profile Evaluates Response and Survival to First-Line Chemotherapy in Lung Cancer. Adv Sci (Weinh) 2021;8:2003263. [PMID: 33643802 DOI: 10.1002/advs.202003263] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
236 Xu Z, Wang R, Li X, Yang L, Peng H, Wang Y, Wang P. RHBDD1 silencing inhibited cell growth and invasion of non-small cell lung cancer by mediating ZEB1/PI3K/AKT signaling pathway. J Mol Histol 2021;52:503-10. [PMID: 33515112 DOI: 10.1007/s10735-020-09943-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
237 Khaledian B, Taguchi A, Shin-Ya K, Kondo-Ida L, Kagaya N, Suzuki M, Kajino T, Yamaguchi T, Shimada Y, Takahashi T. Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma. Cancer Sci 2021;112:1225-34. [PMID: 33370472 DOI: 10.1111/cas.14786] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
238 Shakil MS, Parveen S, Rana Z, Walsh F, Movassaghi S, Söhnel T, Azam M, Shaheen MA, Jamieson SMF, Hanif M, Rosengren RJ, Hartinger CG. High Antiproliferative Activity of Hydroxythiopyridones over Hydroxypyridones and Their Organoruthenium Complexes. Biomedicines 2021;9:123. [PMID: 33513800 DOI: 10.3390/biomedicines9020123] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
239 Huang C, Li Z, Zhu J, Chen X, Hao Y, Yang R, Huang R, Zhou J, Wang Z, Xiao W, Zheng C, Wang Y. Systems pharmacology dissection of Epimedium targeting tumor microenvironment to enhance cytotoxic T lymphocyte responses in lung cancer. Aging (Albany NY) 2021;13:2912-40. [PMID: 33460401 DOI: 10.18632/aging.202410] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
240 Hsu CC, Yang AY, Chen JY, Tsai HH, Lin SH, Tai PC, Huang MH, Hsu WH, Lin AM, Yang JC. Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells. Cancers (Basel) 2021;13:E272. [PMID: 33450879 DOI: 10.3390/cancers13020272] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
241 Zhang W, Feng G. C1QTNF6 regulates cell proliferation and apoptosis of NSCLC in vitro and in vivo. Biosci Rep 2021;41:BSR20201541. [PMID: 33269376 DOI: 10.1042/BSR20201541] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
242 Ohtaki Y, Shimizu K, Suzuki H, Suzuki K, Tsuboi M, Mitsudomi T, Takao M, Murakawa T, Ito H, Yoshimura K, Okada M, Chida M; Japanese Association for Chest Surgery. Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment. Lung Cancer 2021;153:108-16. [PMID: 33482408 DOI: 10.1016/j.lungcan.2020.12.037] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
243 Luo K, Zhang L, Liao Y, Zhou H, Yang H, Luo M, Qing C. Effects and mechanisms of Eps8 on the biological behaviour of malignant tumours (Review). Oncol Rep 2021;45:824-34. [PMID: 33432368 DOI: 10.3892/or.2021.7927] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
244 Kerr DL, Haderk F, Bivona TG. Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment. Curr Opin Chem Biol 2021;62:1-12. [PMID: 33418513 DOI: 10.1016/j.cbpa.2020.11.007] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 20.5] [Reference Citation Analysis]
245 Zhang Q, Jiang T, Xiao M, Zhang J, Ying X. Identification of a Novel Osimertinib-Sensitive Mutation, EGFR H773L, in a Chinese Patient With NSCLC. J Thorac Oncol 2020;15:e46-8. [PMID: 32093862 DOI: 10.1016/j.jtho.2019.11.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
246 Qin W, Yu F, Zhou H, Li P, Zhou F, Li HJ, He CX, Xing L, Zhou X, Zhao D, Li PQ, Jin X, Wang QS, He JH, Cao HL. Complex crystal structure determination and anti-non-small-cell lung cancer activity of the Hsp90N inhibitor Debio0932. Acta Crystallogr D Struct Biol 2021;77:86-97. [PMID: 33404528 DOI: 10.1107/S2059798320014990] [Reference Citation Analysis]
247 Zhang J, Song D, Dong Y, Bai L, Gao D, Guo Y, Li F, Yu X, Zhang S. Study on the Changes of Immune Factors in Different Stages of Non-Small Cell Lung Cancer Chemotherapy. ALC 2021;10:57-64. [DOI: 10.4236/alc.2021.104006] [Reference Citation Analysis]
248 Mandal P, Goswami A, Adhikari S, Sarkar S. Modulation of Signaling Pathways by Immunotherapeutics in Lung Cancer. Targeting Cellular Signalling Pathways in Lung Diseases 2021. [DOI: 10.1007/978-981-33-6827-9_10] [Reference Citation Analysis]
249 Zheng Q, Dong H, Mo J, Zhang Y, Huang J, Ouyang S, Shi S, Zhu K, Qu X, Hu W, Liu P, Wang Y, Zhang X. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics 2021;11:824-40. [PMID: 33391507 DOI: 10.7150/thno.49600] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
250 Ito T, Suzuki T, Murakami Y. Mathematical Modeling of the Dimerization of EGFR and ErbB3 in Lung Adenocarcinoma. Springer Proceedings in Mathematics & Statistics 2021. [DOI: 10.1007/978-981-16-4866-3_12] [Reference Citation Analysis]
251 Recondo G, Friboulet L. Therapeutic strategies to overcome ALK resistance in lung cancer. Therapeutic Strategies to Overcome ALK Resistance in Cancer 2021. [DOI: 10.1016/b978-0-12-821774-0.00004-8] [Reference Citation Analysis]
252 Shang JL, Ning SB, Chen YY, Chen TX, Zhang J. MDL-800, an allosteric activator of SIRT6, suppresses proliferation and enhances EGFR-TKIs therapy in non-small cell lung cancer. Acta Pharmacol Sin 2021;42:120-31. [PMID: 32541922 DOI: 10.1038/s41401-020-0442-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
253 Zhang X, Xu X, Ren Y, Yan Y, Wu A. Numerical simulation of circulating tumor cell separation in a dielectrophoresis based Y-Y shaped microfluidic device. Separation and Purification Technology 2021;255:117343. [DOI: 10.1016/j.seppur.2020.117343] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
254 Gao L, Wang L. Future epigenetic treatment strategies. Epigenetic Regulation in Overcoming Chemoresistance 2021. [DOI: 10.1016/b978-0-12-823684-0.00015-3] [Reference Citation Analysis]
255 Hu K, Li K, Lv J, Feng J, Chen J, Wu H, Cheng F, Jiang W, Wang J, Pei H, Chiao PJ, Cai Z, Chen Y, Liu M, Pang X. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. J Clin Invest 2020;130:1752-66. [PMID: 31874110 DOI: 10.1172/JCI124049] [Cited by in Crossref: 102] [Cited by in F6Publishing: 113] [Article Influence: 34.0] [Reference Citation Analysis]
256 Chen Y, Zhou X, Huang C, Li L, Qin Y, Tian Z, He J, Liu H. LncRNA PART1 promotes cell proliferation and progression in non-small-cell lung cancer cells via sponging miR-17-5p. J Cell Biochem 2021;122:315-25. [PMID: 33368623 DOI: 10.1002/jcb.29714] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
257 Schenk EL, Patil T, Pacheco J, Bunn PA Jr. 2020 Innovation-Based Optimism for Lung Cancer Outcomes. Oncologist 2021;26:e454-72. [PMID: 33179378 DOI: 10.1002/onco.13590] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
258 Zhao F, Wei Y, Yan Y, Liu H, Zhou S, Ren B, Liu R. Determination of Crizotinib in Mouse Tissues by LC-MS/MS and Its Application to a Tissue Distribution Study. Int J Anal Chem 2020;2020:8837254. [PMID: 33381185 DOI: 10.1155/2020/8837254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
259 Rodenak-Kladniew B, Castro MA, Crespo R, Galle M, García de Bravo M. Anti-cancer mechanisms of linalool and 1,8-cineole in non-small cell lung cancer A549 cells. Heliyon 2020;6:e05639. [PMID: 33367122 DOI: 10.1016/j.heliyon.2020.e05639] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
260 Boyero L, Sánchez-Gastaldo A, Alonso M, Noguera-Uclés JF, Molina-Pinelo S, Bernabé-Caro R. Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy. Cancers (Basel) 2020;12:E3729. [PMID: 33322522 DOI: 10.3390/cancers12123729] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
261 Nokin MJ, Ambrogio C, Nadal E, Santamaria D. Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer. Trends Cancer 2021;7:410-29. [PMID: 33309239 DOI: 10.1016/j.trecan.2020.11.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
262 Wu X, Gao Y, Bu J, Deng L, Zhang P, Chi M, Jiang L, Shi X, Ning S, Wang G. Identification of Potential Long Non-coding RNA Expression Quantitative Trait Methylations in Lung Adenocarcinoma and Lung Squamous Carcinoma. Front Genet 2020;11:602035. [PMID: 33362860 DOI: 10.3389/fgene.2020.602035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
263 Lou Y, Xu J, Zhang Y, Lu J, Chu T, Zhang X, Wang H, Zhong H, Zhang W, Han B. Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study. Target Oncol 2020;15:175-84. [PMID: 32170554 DOI: 10.1007/s11523-020-00708-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
264 Li X, Su J, Yang Y, Lian W, Deng Z, Yang Z, Chen G, Zhang B, Dong C, Liu X, Li L, Wang Z, Hu Z, Xu Q, Deng X. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant. Eur J Med Chem 2020;207:112755. [PMID: 32882611 DOI: 10.1016/j.ejmech.2020.112755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
265 Yang Y, Zhang X, Wang R, Qin J, Wang J, Li Z, Song X. Osimertinib Resistance With a Novel EGFR L858R/A859S/Y891D Triple Mutation in a Patient With Non-Small Cell Lung Cancer: A Case Report. Front Oncol 2020;10:542277. [PMID: 33324543 DOI: 10.3389/fonc.2020.542277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
266 Huang KC, Chiang SF, Ke TW, Chen WT, Chen TW, Chao KC. The Clinical Relevance of Frequent Germline Genetic Variants Detected by Targeted Sequencing in Patients With Rectal Adenocarcinoma (READ). Cancer Genomics Proteomics 2020;17:291-9. [PMID: 32345670 DOI: 10.21873/cgp.20189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
267 Guerriero I, Monaco G, Coppola V, Orlacchio A. Serum and Glucocorticoid-Inducible Kinase 1 (SGK1) in NSCLC Therapy. Pharmaceuticals (Basel) 2020;13:E413. [PMID: 33266470 DOI: 10.3390/ph13110413] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
268 Fan M, Wu J, Li X, Jiang Y, Wang X, Bie M, Weng Y, Chen S, Chen B, An L, Zhang M, Huang G, Zhu M, Shi Q. CX3 CL1 promotes tumour cell by inducing tyrosine phosphorylation of cortactin in lung cancer. J Cell Mol Med 2021;25:132-46. [PMID: 33191645 DOI: 10.1111/jcmm.15887] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
269 Sobottka B, Weber A. [Molecular tumor diagnostics-current methods, examples of application and future]. Pathologe 2020;41:411-24. [PMID: 32430586 DOI: 10.1007/s00292-020-00793-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
270 Yatabe Y. Pathology and Genome Medicine of the Lung Cancer. JJLC 2020;60:917-921. [DOI: 10.2482/haigan.60.917] [Reference Citation Analysis]
271 Liu T, Han C, Fang P, Zhu H, Wang S, Ma Z, Zhang Q, Xia W, Wang J, Xu L, Yin R. Long non-coding RNAs in lung cancer: implications for lineage plasticity-mediated TKI resistance. Cell Mol Life Sci 2021;78:1983-2000. [PMID: 33170304 DOI: 10.1007/s00018-020-03691-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
272 Wei D, Li C, Ye J, Xiang F, Xu Y, Liu J. Codelivery of survivin inhibitor and chemotherapeutics by tumor-derived microparticles to reverse multidrug resistance in osteosarcoma. Cell Biol Int 2021;45:382-93. [PMID: 33135822 DOI: 10.1002/cbin.11494] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
273 Wang D, Cong J, Fu B, Zheng X, Sun R, Tian Z, Wei H. Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer. Cancer Letters 2020;492:31-43. [DOI: 10.1016/j.canlet.2020.07.043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
274 Zhang S, Bao Y, Shen X, Pan Y, Sun Y, Xiao M, Chen K, Wei H, Zuo J, Saffen D, Zong WX, Sun Y, Wang Z, Wang Y. RNA binding motif protein 10 suppresses lung cancer progression by controlling alternative splicing of eukaryotic translation initiation factor 4H. EBioMedicine 2020;61:103067. [PMID: 33130397 DOI: 10.1016/j.ebiom.2020.103067] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
275 Goecks J, Jalili V, Heiser LM, Gray JW. How Machine Learning Will Transform Biomedicine. Cell 2020;181:92-101. [PMID: 32243801 DOI: 10.1016/j.cell.2020.03.022] [Cited by in Crossref: 117] [Cited by in F6Publishing: 129] [Article Influence: 39.0] [Reference Citation Analysis]
276 H Araujo L, Ferreira CG, Baldotto CS, Mathias C, Castro G Jr, Coudry R. Next-generation sequencing of circulating tumor DNA for metastatic non-small cell lung cancer: a discussion on its implementation in the Brazilian clinical practice. Future Oncol 2021;17:205-13. [PMID: 33052747 DOI: 10.2217/fon-2020-0583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
277 Xu L, Xu Y, Yang M, Li J, Xu F, Chen BL. LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway. BMC Pulm Med 2020;20:266. [PMID: 33059643 DOI: 10.1186/s12890-020-01276-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
278 D'Adamo GL, Widdop JT, Giles EM. The future is now? Clinical and translational aspects of "Omics" technologies. Immunol Cell Biol 2021;99:168-76. [PMID: 32924178 DOI: 10.1111/imcb.12404] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
279 Cadranel J, Fallet V, Baldacci S, Cortot A. Traitement des cancers bronchiques non à petites cellules de stades avancés mutés EGFR : quels inhibiteurs ? Quelles séquences thérapeutiques ? Revue des Maladies Respiratoires Actualités 2020;12:2S195-2S211. [DOI: 10.1016/s1877-1203(20)30100-2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
280 Lamberti G, Andrini E, Sisi M, Rizzo A, Parisi C, Di Federico A, Gelsomino F, Ardizzoni A. Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. Crit Rev Oncol Hematol 2020;156:103119. [PMID: 33053439 DOI: 10.1016/j.critrevonc.2020.103119] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 12.7] [Reference Citation Analysis]
281 Verusingam ND, Chen YC, Lin HF, Liu CY, Lee MC, Lu KH, Cheong SK, Han-Kiat Ong A, Chiou SH, Wang ML. Generation of osimertinib-resistant cells from epidermal growth factor receptor L858R/T790M mutant non-small cell lung carcinoma cell line. J Chin Med Assoc 2021;84:248-54. [PMID: 33009209 DOI: 10.1097/JCMA.0000000000000438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
282 Wang Y, Zhang J, Ren S, Sun D, Huang HY, Wang H, Jin Y, Li F, Zheng C, Yang L, Deng L, Jiang Z, Jiang T, Han X, Hou S, Guo C, Li F, Gao D, Qin J, Gao D, Chen L, Lin SH, Wong KK, Li C, Hu L, Zhou C, Ji H. Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors. Cell Rep 2019;28:512-525.e6. [PMID: 31291585 DOI: 10.1016/j.celrep.2019.06.026] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 14.7] [Reference Citation Analysis]
283 Wei QY, Xu YM, Lau ATY. Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies. Cancers (Basel). 2020;12. [PMID: 32998391 DOI: 10.3390/cancers12102783] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 14.0] [Reference Citation Analysis]
284 He T, Shen H, Wang S, Wang Y, He Z, Zhu L, Du X, Wang D, Li J, Zhong S, Huang W, Yang H. MicroRNA-3613-5p Promotes Lung Adenocarcinoma Cell Proliferation through a RELA and AKT/MAPK Positive Feedback Loop. Mol Ther Nucleic Acids 2020;22:572-83. [PMID: 33230458 DOI: 10.1016/j.omtn.2020.09.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
285 Chuang HH, Hsu JF, Chang HL, Wang PH, Wei PJ, Wu DW, Huang MS, Hsiao M, Yang CJ. Pin1 coordinates HDAC6 upregulation with cell migration in lung cancer cells. Int J Med Sci 2020;17:2635-43. [PMID: 33162791 DOI: 10.7150/ijms.50097] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
286 Wei D, Zhan W, Gao Y, Huang L, Gong R, Wang W, Zhang R, Wu Y, Gao S, Kang T. RAB31 marks and controls an ESCRT-independent exosome pathway. Cell Res 2021;31:157-77. [PMID: 32958903 DOI: 10.1038/s41422-020-00409-1] [Cited by in Crossref: 88] [Cited by in F6Publishing: 97] [Article Influence: 29.3] [Reference Citation Analysis]
287 Zhang X, Chen J, Cheng C, Li P, Cai F, Xu H, Lu Y, Cao N, Liu J, Wang J, Hua ZC, Zhuang H. Aspirin potentiates celecoxib-induced growth inhibition and apoptosis in human non-small cell lung cancer by targeting GRP78 activity. Ther Adv Med Oncol 2020;12:1758835920947976. [PMID: 32994805 DOI: 10.1177/1758835920947976] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
288 Voigt W, Manegold C, Pilz L, Wu YL, Müllauer L, Pirker R, Filipits M, Niklinski J, Petruzelka L, Prosch H. Beyond tissue biopsy: a diagnostic framework to address tumor heterogeneity in lung cancer. Curr Opin Oncol 2020;32:68-77. [PMID: 31714259 DOI: 10.1097/CCO.0000000000000598] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
289 Mizuno K, Tanigawa K, Nohata N, Misono S, Okada R, Asai S, Moriya S, Suetsugu T, Inoue H, Seki N. FAM64A: A Novel Oncogenic Target of Lung Adenocarcinoma Regulated by Both Strands of miR-99a (miR-99a-5p and miR-99a-3p). Cells 2020;9:E2083. [PMID: 32932948 DOI: 10.3390/cells9092083] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
290 Mansuet-lupo A, Garinet S, Damotte D, Alifano M, Blons H, Wislez M, Leroy K. Les réarrangements moléculaires : cibles thérapeutiques en cancérologie thoracique. Bulletin du Cancer 2020;107:896-903. [DOI: 10.1016/j.bulcan.2020.05.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
291 Yang N, Li C, Han X, Feng Z, Qiu F, Han J. Associations of MTA1 expression with CT features, pathology and prognosis of elderly patients with non-small cell lung cancer. Oncol Lett 2020;20:172. [PMID: 32934739 DOI: 10.3892/ol.2020.12034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
292 La Montagna M, Ginn L, Garofalo M. Mechanisms of drug resistance mediated by long non-coding RNAs in non-small-cell lung cancer. Cancer Gene Ther 2021;28:175-87. [PMID: 32843741 DOI: 10.1038/s41417-020-00214-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
293 Pan Z, Chen Q, Zheng X, Wang K, Duan Y, Xiao K, Jia Z, Ding X. JuBei Oral Liquid Induces Mitochondria-Mediated Apoptosis in NSCLC Cells. Onco Targets Ther 2020;13:7585-98. [PMID: 32821122 DOI: 10.2147/OTT.S254464] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
294 Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA, Naeger DM, Bandyopadhyay S, Shah K, Cech L, Thomas NJ, Gupta A, Gonzalez M, Do H, Tan L, Bacaltos B, Gomez-Sjoberg R, Gubens M, Jahan T, Kratz JR, Jablons D, Neff N, Doebele RC, Weissman J, Blakely CM, Darmanis S, Bivona TG. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell 2020;182:1232-1251.e22. [PMID: 32822576 DOI: 10.1016/j.cell.2020.07.017] [Cited by in Crossref: 165] [Cited by in F6Publishing: 185] [Article Influence: 55.0] [Reference Citation Analysis]
295 Lin Z, Pan J, Chen L, Wang X, Chen Y. MiR-140 Resensitizes Cisplatin-Resistant NSCLC Cells to Cisplatin Treatment Through the SIRT1/ROS/JNK Pathway. Onco Targets Ther 2020;13:8149-60. [PMID: 32884297 DOI: 10.2147/OTT.S261799] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
296 Cao N, Lu Y, Liu J, Cai F, Xu H, Chen J, Zhang X, Hua ZC, Zhuang H. Metformin Synergistically Enhanced the Antitumor Activity of Celecoxib in Human Non-Small Cell Lung Cancer Cells. Front Pharmacol 2020;11:1094. [PMID: 32792943 DOI: 10.3389/fphar.2020.01094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
297 Hatami E, Nagesh PKB, Jaggi M, Chauhan SC, Yallapu MM. Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer. Eur J Pharmacol 2020;888:173486. [PMID: 32805254 DOI: 10.1016/j.ejphar.2020.173486] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
298 Ye MF, Lin D, Li WJ, Xu HP, Zhang J. MiR-26a-5p Serves as an Oncogenic MicroRNA in Non-Small Cell Lung Cancer by Targeting FAF1. Cancer Manag Res 2020;12:7131-42. [PMID: 32848467 DOI: 10.2147/CMAR.S261131] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
299 Wang C, Ding S, Sun B, Shen L, Xiao L, Han Z, Huang H. Hsa-miR-4271 downregulates the expression of constitutive androstane receptor and enhances in vivo the sensitivity of non-small cell lung cancer to gefitinib. Pharmacol Res 2020;161:105110. [PMID: 32755614 DOI: 10.1016/j.phrs.2020.105110] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
300 Fang W, Huang Y, Gu W, Gan J, Wang W, Zhang S, Wang K, Zhan J, Yang Y, Huang Y, Zhao H, Zhang L. PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy. Transl Lung Cancer Res 2020;9:1258-67. [PMID: 32953503 DOI: 10.21037/tlcr-20-141] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
301 Luo R, Song J, Xiao X, Xie Z, Zhao Z, Zhang W, Miao S, Tang Y, Ran L. Identifying CpG methylation signature as a promising biomarker for recurrence and immunotherapy in non-small-cell lung carcinoma. Aging (Albany NY) 2020;12:14649-76. [PMID: 32723974 DOI: 10.18632/aging.103517] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
302 Zaidi M, Lizneva D, Gera S, Taneja C, Korkmaz F, Gumerova A, Ievleva K, Ahmad N, Ryu V, Sun L, Kim SM, New MI, Haider S, Iqbal J, Rosen C, Yuen T. Beyond bone biology: Lessons from team science. J Orthop Res 2020;38:2331-8. [PMID: 32519816 DOI: 10.1002/jor.24771] [Reference Citation Analysis]
303 Wang W, Hao Y, Liu Y, Li R, Huang DB, Pan YY. Nanomedicine in lung cancer: Current states of overcoming drug resistance and improving cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;13:e1654. [PMID: 32700465 DOI: 10.1002/wnan.1654] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
304 Chen K, Zhang F, Pan G, Sheng J, Ye J, Xu Y, Yu X, Huang Z, Fan Y. A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib. Clin Lung Cancer 2021;22:e1-4. [PMID: 32778510 DOI: 10.1016/j.cllc.2020.07.007] [Reference Citation Analysis]
305 Xue WX, Zhang MY, Rui Li, Liu X, Yin YH, Qu YQ. Serum miR-1228-3p and miR-181a-5p as Noninvasive Biomarkers for Non-Small Cell Lung Cancer Diagnosis and Prognosis. Biomed Res Int 2020;2020:9601876. [PMID: 32724822 DOI: 10.1155/2020/9601876] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
306 Vichas A, Nkinsi NT, Riley A, Parrish PC, Duke F, Chen J, Fung I, Watson J, Rees M, Lee JK, Piccioni F, Hatch EM, Berger AH. An integrative oncogene-dependency map identifies unique vulnerabilities of oncogenic EGFR, KRAS, and RIT1 in lung cancer.. [DOI: 10.1101/2020.07.03.187310] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
307 Zhao L, Qiu T, Jiang D, Xu H, Zou L, Yang Q, Chen C, Jiao B. SGCE Promotes Breast Cancer Stem Cells by Stabilizing EGFR. Adv Sci (Weinh) 2020;7:1903700. [PMID: 32714745 DOI: 10.1002/advs.201903700] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
308 Xu J, Zhang C, Wang X, Zhai L, Ma Y, Mao Y, Qian K, Sun C, Liu Z, Jiang S, Wang M, Feng L, Zhao L, Liu P, Wang B, Zhao X, Xie H, Yang X, Zhao L, Chang Y, Jia J, Wang X, Zhang Y, Wang Y, Yang Y, Wu Z, Yang L, Liu B, Zhao T, Ren S, Sun A, Zhao Y, Ying W, Wang F, Wang G, Zhang Y, Cheng S, Qin J, Qian X, Wang Y, Li J, He F, Xiao T, Tan M. Integrative Proteomic Characterization of Human Lung Adenocarcinoma. Cell 2020;182:245-261.e17. [DOI: 10.1016/j.cell.2020.05.043] [Cited by in Crossref: 120] [Cited by in F6Publishing: 138] [Article Influence: 40.0] [Reference Citation Analysis]
309 Li C, Yao L, Gong J, Pang H, Shan Q, Wang Z, Lu J, Wang Z. Efficacy of Gefitinib Combined with 125I Radioactive Particles in the Treatment of Transplanted Lung Cancer Tumors in Nude Mice. Cardiovasc Intervent Radiol 2020;43:1364-70. [PMID: 32607617 DOI: 10.1007/s00270-020-02550-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
310 König D, Meier UR, Klaeser B, Savic S, Pless M. Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC. Case Rep Oncol 2020;13:729-32. [PMID: 32774266 DOI: 10.1159/000507850] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
311 Petrek H, Yu AM. MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential. Pharmacol Res Perspect 2019;7:e00528. [PMID: 31859460 DOI: 10.1002/prp2.528] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 13.3] [Reference Citation Analysis]
312 Brassart-Pasco S, Dalstein V, Brassart B, Dewolf M, Clavel C, Oudart JB. Immunotherapy in non-small-cell lung cancer: from targeted molecules to resistance patterns. Pharmacogenomics 2020;21:705-20. [PMID: 32567537 DOI: 10.2217/pgs-2020-0021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
313 García-Fernández C, Fornaguera C, Borrós S. Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy. Cancers (Basel) 2020;12:E1609. [PMID: 32570729 DOI: 10.3390/cancers12061609] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
314 Wang J, Li J, Xiao Y, Fu B, Qin Z. TPP-based mitocans: a potent strategy for anticancer drug design. RSC Med Chem 2020;11:858-75. [PMID: 33479681 DOI: 10.1039/c9md00572b] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
315 Lu X, Smaill JB, Ding K. Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. J Med Chem 2020;63:10726-41. [PMID: 32432477 DOI: 10.1021/acs.jmedchem.0c00507] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
316 Chen Y, Chen C, Zhang X, He C, Zhao P, Li M, Fan T, Yan R, Lu Y, Lee RJ, Khan MW, Sarfraz M, Ma X, Yang T, Xiang G. Platinum complexes of curcumin delivered by dual-responsive polymeric nanoparticles improve chemotherapeutic efficacy based on the enhanced anti-metastasis activity and reduce side effects. Acta Pharm Sin B 2020;10:1106-21. [PMID: 32642416 DOI: 10.1016/j.apsb.2019.10.011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 12.7] [Reference Citation Analysis]
317 Mao S, Li Y, Lu Z, Che Y, Huang J, Lei Y, Wang Y, Wang X, Liu C, Zheng S, Li N, Li J, Sun N, He J. Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma. Cell Oncol (Dordr) 2020;43:681-94. [PMID: 32462608 DOI: 10.1007/s13402-020-00515-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
318 Panneerselvam J, Mohandoss P, Patel R, Gillan H, Li M, Kumar K, Nguyen D, Weygant N, Qu D, Pitts K, Lightfoot S, Rao C, Houchen C, Bronze M, Chandrakesan P. DCLK1 Regulates Tumor Stemness and Cisplatin Resistance in Non-small Cell Lung Cancer via ABCD-Member-4. Mol Ther Oncolytics 2020;18:24-36. [PMID: 32637578 DOI: 10.1016/j.omto.2020.05.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
319 Hsu PC, Yang CT, Jablons DM, You L. The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC). Cancers (Basel) 2020;12:E1361. [PMID: 32466572 DOI: 10.3390/cancers12061361] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
320 Xu E, David EA, Ding L, Atay SM, McFadden PM, Wightman SC, Kim AW. Sequence of biologic therapies and surgery affects survival in non-small cell lung cancer. J Surg Oncol 2020;122:320-7. [PMID: 32436293 DOI: 10.1002/jso.25937] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
321 Zhang M, Jang H, Nussinov R. PI3K inhibitors: review and new strategies. Chem Sci 2020;11:5855-65. [PMID: 32953006 DOI: 10.1039/d0sc01676d] [Cited by in Crossref: 53] [Cited by in F6Publishing: 60] [Article Influence: 17.7] [Reference Citation Analysis]
322 Zhang T, Qu R, Chan S, Lai M, Tong L, Feng F, Chen H, Song T, Song P, Bai G, Liu Y, Wang Y, Li Y, Su Y, Shen Y, Sun Y, Chen Y, Geng M, Ding K, Ding J, Xie H. Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol Cancer 2020;19:90. [PMID: 32404161 DOI: 10.1186/s12943-020-01202-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
323 Yuan B, Zhao J, Zhou C, Wang X, Zhu B, Zhuo M, Dong X, Feng J, Yi C, Yang Y, Zhang H, Zhou W, Chen Z, Yang S, Ai X, Chen K, Cui X, Liu D, Shi C, Wu W, Zhang Y, Chang L, Li J, Chen R, Yang S. Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib. Front Oncol 2020;10:729. [PMID: 32477948 DOI: 10.3389/fonc.2020.00729] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
324 Singh R, Peng S, Viswanath P, Sambandam V, Shen L, Rao X, Fang B, Wang J, Johnson FM. Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis. EMBO Mol Med 2019;11:e9960. [PMID: 31040125 DOI: 10.15252/emmm.201809960] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
325 Kyakulaga AH, Aqil F, Munagala R, Gupta RC. Synergistic combinations of paclitaxel and withaferin A against human non-small cell lung cancer cells. Oncotarget 2020;11:1399-416. [PMID: 32362998 DOI: 10.18632/oncotarget.27519] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
326 Stockhammer P, Ho CSL, Hegedus L, Lotz G, Molnár E, Bankfalvi A, Herold T, Kalbourtzis S, Ploenes T, Eberhardt WEE, Schuler M, Aigner C, Schramm A, Hegedus B. HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model. Lung Cancer 2020;144:20-9. [PMID: 32353632 DOI: 10.1016/j.lungcan.2020.04.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
327 Morales Torres C, Wu MY, Hobor S, Wainwright EN, Martin MJ, Patel H, Grey W, Grönroos E, Howell S, Carvalho J, Snijders AP, Bustin M, Bonnet D, Smith PD, Swanton C, Howell M, Scaffidi P. Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis. Nat Commun 2020;11:1792. [PMID: 32286289 DOI: 10.1038/s41467-020-15615-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
328 Diao Z, Han Y, Zhang R, Li J. Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs. Biochim Biophys Acta Rev Cancer 2020;1873:188363. [PMID: 32275933 DOI: 10.1016/j.bbcan.2020.188363] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
329 Riccardo F, Barutello G, Petito A, Tarone L, Conti L, Arigoni M, Musiu C, Izzo S, Volante M, Longo DL, Merighi IF, Papotti M, Cavallo F, Quaglino E. Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas ​. Vaccines (Basel) 2020;8:E166. [PMID: 32268572 DOI: 10.3390/vaccines8020166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
330 Zhao Z, Li L, Wang Z, Duan J, Bai H, Wang J. The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis. J Cancer 2020;11:3106-13. [PMID: 32231715 DOI: 10.7150/jca.38411] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
331 Kwon S, Lee D, Gopal S, Ku A, Moon H, Dordick JS. Three‐dimensional in vitro cell culture devices using patient‐derived cells for high‐throughput screening of drug combinations. Med Devices Sens 2020;3. [DOI: 10.1002/mds3.10067] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
332 Oxnard G, Yang J, Yu H, Kim S, Saka H, Horn L, Goto K, Ohe Y, Mann H, Thress K, Frigault M, Vishwanathan K, Ghiorghiu D, Ramalingam S, Ahn M. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Annals of Oncology 2020;31:507-16. [DOI: 10.1016/j.annonc.2020.01.013] [Cited by in Crossref: 155] [Cited by in F6Publishing: 136] [Article Influence: 51.7] [Reference Citation Analysis]
333 Sobottka B, Weber A. Molekulare Tumordiagnostik – aktuelle Methoden, Anwendungsbeispiele und Ausblick. Onkologe 2020;26:373-386. [DOI: 10.1007/s00761-020-00748-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
334 Zhou Tran Y, Minozada R, Cao X, Johansson HJ, Branca RM, Seashore-Ludlow B, Orre LM. Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC. Mol Cell Proteomics 2020;19:928-43. [PMID: 32234966 DOI: 10.1074/mcp.RA120.002036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
335 Yu C, Cheng Z, Cui S, Mao X, Li B, Fu Y, Wang H, Jin H, Ye Q, Zhao X, Jiang L, Qin W. circFOXM1 promotes proliferation of non-small cell lung carcinoma cells by acting as a ceRNA to upregulate FAM83D. J Exp Clin Cancer Res 2020;39:55. [PMID: 32228656 DOI: 10.1186/s13046-020-01555-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
336 Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol 2020;17:395-417. [PMID: 32203277 DOI: 10.1038/s41571-020-0341-y] [Cited by in Crossref: 488] [Cited by in F6Publishing: 539] [Article Influence: 162.7] [Reference Citation Analysis]
337 Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther 2020;5:22. [PMID: 32296018 DOI: 10.1038/s41392-020-0116-z] [Cited by in Crossref: 383] [Cited by in F6Publishing: 429] [Article Influence: 127.7] [Reference Citation Analysis]
338 Ni D, Li Y, Qiu Y, Pu J, Lu S, Zhang J. Combining Allosteric and Orthosteric Drugs to Overcome Drug Resistance. Trends Pharmacol Sci 2020;41:336-48. [PMID: 32171554 DOI: 10.1016/j.tips.2020.02.001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 14.0] [Reference Citation Analysis]
339 Du X, Wang T, Wang Z, Wu X, Gu Y, Huang Q, Wang J, Xie J. 5-HT7 Receptor Contributes to Proliferation, Migration and Invasion in NSCLC Cells. Onco Targets Ther 2020;13:2139-51. [PMID: 32210580 DOI: 10.2147/OTT.S244339] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
340 Kong X, Hu S, Yuan Y, Du Y, Zhu Z, Song Z, Lu S, Zhao C, Yan D. Analysis of lncRNA, miRNA and mRNA-associated ceRNA networks and identification of potential drug targets for drug-resistant non-small cell lung cancer. J Cancer 2020;11:3357-68. [PMID: 32231742 DOI: 10.7150/jca.40729] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
341 Sato H, Schoenfeld AJ, Siau E, Lu YC, Tai H, Suzawa K, Kubota D, Lui AJW, Qeriqi B, Mattar M, Offin M, Sakaguchi M, Toyooka S, Drilon A, Rosen NX, Kris MG, Solit D, De Stanchina E, Davare MA, Riely GJ, Ladanyi M, Somwar R. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions. Clin Cancer Res 2020;26:2932-45. [PMID: 32122926 DOI: 10.1158/1078-0432.CCR-19-3321] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
342 Zhu L, Liang J, Xia B, Xu Y, Qian Z, Ma S, Zhang S. Identification of somatic copy number variations in plasma cell free DNA correlating with intrinsic resistances to EGFR targeted therapy in T790M negative non-small cell lung cancer. J Thorac Dis 2020;12:883-92. [PMID: 32274156 DOI: 10.21037/jtd.2019.12.97] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
343 Zewdu R, Mehrabad EM, Ingram K, Fang P, Gillis KL, Camolotto SA, Orstad G, Jones A, Mendoza MC, Spike BT, Snyder EL. An NKX2-1/ERK/WNT feedback loop modulates gastric identity and response to targeted therapy in lung adenocarcinoma.. [DOI: 10.1101/2020.02.25.965004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
344 Jiang L, Wang X, Wang Y, Xu F, Zhang Z, Ding K, Lu X. The synthesis and biological evaluation of sanguinarine derivatives as anti-non-small cell lung cancer agents. RSC Med Chem 2020;11:293-6. [PMID: 33479636 DOI: 10.1039/c9md00494g] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
345 Nigro A, Ricciardi L, Salvato I, Sabbatino F, Vitale M, Crescenzi MA, Montico B, Triggiani M, Pepe S, Stellato C, Casolaro V, Dal Col J. Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC. Front Immunol 2019;10:3135. [PMID: 32082304 DOI: 10.3389/fimmu.2019.03135] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
346 Pinto JA, Raez LE, Domingo G. Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer. Expert Rev Respir Med 2020;14:385-90. [PMID: 31971859 DOI: 10.1080/17476348.2020.1721285] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
347 Fan Q, Wang Q, Cai R, Yuan H, Xu M. The ubiquitin system: orchestrating cellular signals in non-small-cell lung cancer. Cell Mol Biol Lett 2020;25:1. [PMID: 31988639 DOI: 10.1186/s11658-019-0193-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
348 Li L, Hu M, Wang T, Chen H, Xu L. Repositioning Aspirin to Treat Lung and Breast Cancers and Overcome Acquired Resistance to Targeted Therapy. Front Oncol 2019;9:1503. [PMID: 31993373 DOI: 10.3389/fonc.2019.01503] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
349 Persky NS, Hernandez D, Do Carmo M, Brenan L, Cohen O, Kitajima S, Nayar U, Walker A, Pantel S, Lee Y, Cordova J, Sathappa M, Zhu C, Hayes TK, Ram P, Pancholi P, Mikkelsen TS, Barbie DA, Yang X, Haq R, Piccioni F, Root DE, Johannessen CM. Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases. Nat Struct Mol Biol 2020;27:92-104. [PMID: 31925410 DOI: 10.1038/s41594-019-0358-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
350 Yu JJ, Zhou DD, Cui B, Zhang C, Tan FW, Chang S, Li K, Lv XX, Zhang XW, Shang S, Xiang YJ, Chen F, Yu JM, Liu SS, Wang F, Hu ZW, Hua F. Disruption of the EGFR-SQSTM1 interaction by a stapled peptide suppresses lung cancer via activating autophagy and inhibiting EGFR signaling. Cancer Lett 2020;474:23-35. [PMID: 31931029 DOI: 10.1016/j.canlet.2020.01.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
351 Jiang Y, Cheng W, Li L, Zhou L, Liang Y, Zhang W, Chen W, Wang S, Zhao H, Chen G, Zhou W, Ji G, Zhang Y, Hoffman RM, Wang M, Jia L. Effective targeting of the ubiquitin-like modifier NEDD8 for lung adenocarcinoma treatment. Cell Biol Toxicol 2020;36:349-64. [PMID: 31907687 DOI: 10.1007/s10565-019-09503-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
352 Pan Z, Wang K, Chen Q, Zheng X, Song Z, Ding X. SFI Enhances Therapeutic Efficiency of Gefitinib: An Insight into Reversal of Resistance to Targeted Therapy in Non-small Cell Lung Cancer Cells. J Cancer 2020;11:334-44. [PMID: 31897229 DOI: 10.7150/jca.32989] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
353 Luo L, Luo X, Chen W, Liang C, Yao S, Huang W, Liu C, Ge Y, Lin X, Li Z. Consistency Analysis of Programmed Death-Ligand 1 Expression between Primary and Metastatic Non-Small Cell Lung Cancer: A Retrospective Study. J Cancer 2020;11:974-82. [PMID: 31949500 DOI: 10.7150/jca.34793] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
354 Korkmaz F, Hadelia E, Gera S, Taneja C, Mathew M, Gumerova A, Ahmad N, Sant D, Ievleva K, Ji Y, Ryu V, Sun L, New M, Kim S, Iqbal J, Haider S, Lizneva D, Yuen T, Zaidi M. Convergence Research Unmasks Drug Targets Beyond Bone. Encyclopedia of Bone Biology 2020. [DOI: 10.1016/b978-0-12-801238-3.62274-2] [Reference Citation Analysis]
355 Tulpule A, Guan J, Neel D, Lin YP, Heslin A, Allegakoen H, Perati S, Ramirez AD, Shi X, Yang B, Feng S, Makhija S, Brown D, Huang B, Bivona T. Kinase-Mediated RAS Signaling Via Membraneless Cytoplasmic Protein Granules. SSRN Journal. [DOI: 10.2139/ssrn.3578156] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
356 Huang Z, Ma Y, Zhang P, Si J, Xiong Y, Yang Y. Long non-coding RNA H19 confers resistance to gefitinib via miR-148b-3p/DDAH1 axis in lung adenocarcinoma. Anti-Cancer Drugs 2020;31:44-54. [DOI: 10.1097/cad.0000000000000831] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
357 An G, Morris ME. Efflux transporters in cancer resistance: Molecular and functional characterization of breast cancer resistance protein. Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy 2020. [DOI: 10.1016/b978-0-12-816434-1.00003-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
358 Yang K, Chen Y, Zhou J, Ma L, Shan Y, Cheng X, Wang Y, Zhang Z, Ji X, Chen L, Dai H, Zhu B, Li C, Tao Z, Hu X, Yin W. Ursolic acid promotes apoptosis and mediates transcriptional suppression of CT45A2 gene expression in non-small-cell lung carcinoma harbouring EGFR T790M mutations. Br J Pharmacol 2019;176:4609-24. [PMID: 31322286 DOI: 10.1111/bph.14793] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
359 Pasini L, Ulivi P. Extracellular Vesicles in Non-Small-Cell Lung Cancer: Functional Role and Involvement in Resistance to Targeted Treatment and Immunotherapy. Cancers (Basel) 2019;12:E40. [PMID: 31877735 DOI: 10.3390/cancers12010040] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
360 Cervantes-Madrid D, Szydzik J, Lind DE, Borenäs M, Bemark M, Cui J, Palmer RH, Hallberg B. Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells. Sci Rep 2019;9:19353. [PMID: 31852910 DOI: 10.1038/s41598-019-55060-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
361 Maynard A, Mccoach CE, Rotow JK, Harris L, Haderk F, Kerr L, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA, Naeger D, Thomas NJ, Gupta A, Gonzalez M, Do H, Tan L, Gomez-sjoberg R, Gubens M, Jahan T, Kratz JR, Jablons D, Neff N, Doebele RC, Weissman J, Blakely CM, Darmanis S, Bivona TG. Heterogeneity and targeted therapy-induced adaptations in lung cancer revealed by longitudinal single-cell RNA sequencing.. [DOI: 10.1101/2019.12.08.868828] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
362 Ding B, Haidurov A, Chawla A, Parmigiani A, van de Kamp G, Dalina A, Yuan F, Lee JH, Chumakov PM, Grossman SR, Budanov AV. p53-inducible SESTRINs might play opposite roles in the regulation of early and late stages of lung carcinogenesis. Oncotarget 2019;10:6997-7009. [PMID: 31857853 DOI: 10.18632/oncotarget.27367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
363 Qiu Y, He X, Li Z, Jiang Y, Jia Y. Efficacy of early combination of local radiotherapy and GM-CSF for advanced non-small cell lung cancer treated with icotinib. Ir J Med Sci 2020;189:791-7. [PMID: 31797203 DOI: 10.1007/s11845-019-02137-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
364 Fumagalli C, Guerini-Rocco E, Barberis M. Broad-based genomic sequencing in advanced non-small cell lung cancer in the dock. Transl Lung Cancer Res 2019;8:S360-3. [PMID: 32038915 DOI: 10.21037/tlcr.2019.04.16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
365 Bland AR, Bower RL, Nimick M, Hawkins BC, Rosengren RJ, Ashton JC. Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer. European Journal of Pharmacology 2019;865:172749. [DOI: 10.1016/j.ejphar.2019.172749] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
366 Kim Y, Baek D, Lee S, Park D, Kang HN, Cho BC, Kim Y. Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer. Cancer Letters 2019;466:23-34. [DOI: 10.1016/j.canlet.2019.09.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
367 Zeng H, Castillo-Cabrera J, Manser M, Lu B, Yang Z, Strande V, Begue D, Zamponi R, Qiu S, Sigoillot F, Wang Q, Lindeman A, Reece-Hoyes JS, Russ C, Bonenfant D, Jiang X, Wang Y, Cong F. Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC. Elife 2019;8:e50223. [PMID: 31741433 DOI: 10.7554/eLife.50223] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
368 Liu WJ, Du Y, Wen R, Yang M, Xu J. Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. Pharmacol Ther 2020;206:107438. [PMID: 31715289 DOI: 10.1016/j.pharmthera.2019.107438] [Cited by in Crossref: 53] [Cited by in F6Publishing: 65] [Article Influence: 13.3] [Reference Citation Analysis]
369 Karuppasamy R, Veerappapillai S, Maiti S, Shin WH, Kihara D. Current progress and future perspectives of polypharmacology : From the view of non-small cell lung cancer. Semin Cancer Biol 2021;68:84-91. [PMID: 31698087 DOI: 10.1016/j.semcancer.2019.10.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
370 Qiu Z, Ye B, Zhao S, Li X, Li L, Mo X, Li W. Non-canonical Raf-1/p70S6K signalling in non-small-cell lung cancer. J Cell Mol Med 2019;23:7632-40. [PMID: 31541523 DOI: 10.1111/jcmm.14636] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
371 Gong S, Qu X, Yang S, Zhou S, Li P, Zhang Q. RFC3 induces epithelial‑mesenchymal transition in lung adenocarcinoma cells through the Wnt/β‑catenin pathway and possesses prognostic value in lung adenocarcinoma. Int J Mol Med 2019;44:2276-88. [PMID: 31661124 DOI: 10.3892/ijmm.2019.4386] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
372 Bolan PO, Zviran A, Brenan L, Schiffman JS, Dusaj N, Goodale A, Piccioni F, Johannessen CM, Landau DA. Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization. Cell Syst 2020;10:52-65.e7. [PMID: 31668800 DOI: 10.1016/j.cels.2019.10.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
373 Gao X, Zhu J, Chen L, Jiang Y, Zhou X, Shuai J, Zhao Y. Clinical And Imageological Features Of Lung Squamous Cell Carcinoma With EGFR Mutations. Cancer Manag Res 2019;11:9017-24. [PMID: 31695493 DOI: 10.2147/CMAR.S223021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
374 Yang H, Zhang J, Zhang L, Wen X, Luo Y, Yao D, Cheng T, Cheng H, Wang H, Lou F, Guo J, Liang X, Cao S, Chen J. Comprehensive analysis of genomic alterations detected by next-generation sequencing-based tissue and circulating tumor DNA assays in Chinese patients with non-small cell lung cancer. Oncol Lett 2019;18:4762-70. [PMID: 31611986 DOI: 10.3892/ol.2019.10791] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
375 Fan G, Xu P, Tu P. MiR-1827 functions as a tumor suppressor in lung adenocarcinoma by targeting MYC and FAM83F. J Cell Biochem 2020;121:1675-89. [PMID: 31595558 DOI: 10.1002/jcb.29402] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
376 Zhang J, Song Y, Liang Y, Zou H, Zuo P, Yan M, Jing S, Li T, Wang Y, Li D, Zhang T, Wei Z. Cucurbitacin IIa interferes with EGFR-MAPK signaling pathway leads to proliferation inhibition in A549 cells. Food and Chemical Toxicology 2019;132:110654. [DOI: 10.1016/j.fct.2019.110654] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
377 Cadranel J, Fallet V, Baldacci S, Cortot A. Traitement des cancers bronchiques non à petites cellules de stades avancés mutés EGFR: quelle(s) séquence(s) ? Revue des Maladies Respiratoires Actualités 2019;11:364-379. [DOI: 10.1016/s1877-1203(19)30106-5] [Reference Citation Analysis]
378 Lei HM, Zhang KR, Wang CH, Wang Y, Zhuang GL, Lu LM, Zhang J, Shen Y, Chen HZ, Zhu L. Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas. Theranostics 2019;9:7122-39. [PMID: 31695757 DOI: 10.7150/thno.35729] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
379 Müller N, Brägelmann J, Lorenz C, Michel UP, Plenker D, Ortiz-cuaran S, Weiss J, Büttner R, Peifer M, Thomas RK, Sos ML, Berg J. In vitro model for resistance in oncogene-dependent tumors at the limit of radiological detectability.. [DOI: 10.1101/756593] [Reference Citation Analysis]
380 Jimbo T, Hatanaka M, Komatsu T, Taira T, Kumazawa K, Maeda N, Suzuki T, Ota M, Haginoya N, Isoyama T, Fujiwara K. DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model. Oncotarget 2019;10:5152-67. [PMID: 31497246 DOI: 10.18632/oncotarget.27114] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
381 Craig M, Kaveh K, Woosley A, Brown AS, Goldman D, Eton E, Mehta RM, Dhawan A, Arai K, Rahman MM, Chen S, Nowak MA, Goldman A. Cooperative adaptation to therapy (CAT) confers resistance in heterogeneous non-small cell lung cancer. PLoS Comput Biol 2019;15:e1007278. [PMID: 31449515 DOI: 10.1371/journal.pcbi.1007278] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
382 Lai Y, Zeng T, Liang X, Wu W, Zhong F, Wu W. Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy. Cancer Cell Int 2019;19:221. [PMID: 31462894 DOI: 10.1186/s12935-019-0939-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
383 Karachaliou N, Codony-Servat J, Bracht JWP, Ito M, Filipska M, Pedraz C, Chaib I, Bertran-Alamillo J, Cardona AF, Molina MA, Rosell R. Characterising acquired resistance to erlotinib in non-small cell lung cancer patients. Expert Rev Respir Med 2019;13:1019-28. [PMID: 31411906 DOI: 10.1080/17476348.2019.1656068] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
384 Kitazono S, Sakai K, Yanagitani N, Ariyasu R, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Nishikawa S, Uchibori K, Horiike A, Nishio K, Nishio M. Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients. Cancer Sci 2019;110:3350-7. [PMID: 31361375 DOI: 10.1111/cas.14153] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
385 Piper AJ, Clark JL, Mercado-Matos J, Matthew-Onabanjo AN, Hsieh CC, Akalin A, Shaw LM. Insulin Receptor Substrate-1 (IRS-1) and IRS-2 expression levels are associated with prognosis in non-small cell lung cancer (NSCLC). PLoS One 2019;14:e0220567. [PMID: 31393907 DOI: 10.1371/journal.pone.0220567] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
386 Liu X, Li C, Yang Y, Liu X, Li R, Zhang M, Yin Y, Qu Y. Synaptotagmin 7 in twist-related protein 1-mediated epithelial - Mesenchymal transition of non-small cell lung cancer. EBioMedicine 2019;46:42-53. [PMID: 31395502 DOI: 10.1016/j.ebiom.2019.07.071] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
387 Santarpia M, Menis J, Chaib I, Gonzalez Cao M, Rosell R. Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer. Expert Rev Clin Pharmacol 2019;12:831-40. [PMID: 31356117 DOI: 10.1080/17512433.2019.1649136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
388 Zugazagoitia J, Gómez-rueda A, Jantus-lewintre E, Isla D, Camps C, Ramos I, Trigo JM, Bernabé R, Juan-vidal O, Sanchez-torres JM, García-campelo R, Provencio M, Felip E, de Castro J, Faull I, Lanman RB, Ponce-aix S, Paz-ares L, Garrido P. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. Lung Cancer 2019;134:72-8. [DOI: 10.1016/j.lungcan.2019.05.032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
389 Finley LWS. Metabolic signal curbs cancer-cell migration. Nature 2019;571:39-40. [PMID: 31263261 DOI: 10.1038/d41586-019-01934-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
390 Lee PC, Fang YF, Yamaguchi H, Wang WJ, Chen TC, Hong X, Ke B, Xia W, Wei Y, Zha Z, Wang Y, Kuo HP, Wang CW, Tu CY, Chen CH, Huang WC, Chiang SF, Nie L, Hou J, Chen CT, Huo L, Yang WH, Deng R, Nakai K, Hsu YH, Chang SS, Chiu TJ, Tang J, Zhang R, Wang L, Fang B, Chen T, Wong KK, Hsu JL, Hung MC. Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. Cancer Cell 2018;34:954-969.e4. [PMID: 30537515 DOI: 10.1016/j.ccell.2018.11.007] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
391 Cai L, Bai H, Duan J, Wang Z, Gao S, Wang D, Wang S, Jiang J, Han J, Tian Y, Zhang X, Ye H, Li M, Huang B, He J, Wang J. Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer. J Immunother Cancer 2019;7:198. [PMID: 31349879 DOI: 10.1186/s40425-019-0660-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
392 Tulpule A, Guan J, Neel DS, Lin YP, Heslin A, Allegakoen HR, Perati S, Ramirez AD, Shi X, Yang B, Feng S, Makhija S, Brown D, Huang B, Bivona TG. Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules.. [DOI: 10.1101/704312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
393 Morris TA, Khoo C, Solomon BJ. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors. Drugs 2019;79:1277-86. [DOI: 10.1007/s40265-019-01164-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
394 Wu T, Chen W, Yang Z, Tan H, Wang J, Xiao X, Li M, Zhao M. DNA terminal structure-mediated enzymatic reaction for ultra-sensitive discrimination of single nucleotide variations in circulating cell-free DNA. Nucleic Acids Res 2018;46:e24. [PMID: 29190359 DOI: 10.1093/nar/gkx1218] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
395 Tavassoly I, Hu Y, Zhao S, Mariottini C, Boran A, Chen Y, Li L, Tolentino RE, Jayaraman G, Goldfarb J, Gallo J, Iyengar R. Genomic signatures defining responsiveness to allopurinol and combination therapy for lung cancer identified by systems therapeutics analyses. Mol Oncol 2019;13:1725-43. [PMID: 31116490 DOI: 10.1002/1878-0261.12521] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
396 Roys A, Chang X, Liu Y, Xu X, Wu Y, Zuo D. Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer. Cancer Chemother Pharmacol 2019;84:679-88. [DOI: 10.1007/s00280-019-03902-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
397 Mohsenzadegan M, Peng RW, Roudi R. Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape. J Cell Physiol 2020;235:74-86. [PMID: 31222740 DOI: 10.1002/jcp.28977] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
398 Blucher AS, McWeeney SK, Stein L, Wu G. Visualization of drug target interactions in the contexts of pathways and networks with ReactomeFIViz. F1000Res 2019;8:908. [PMID: 31372215 DOI: 10.12688/f1000research.19592.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
399 Chen S, Cao Q, Wen W, Wang H. Targeted therapy for hepatocellular carcinoma: Challenges and opportunities. Cancer Lett. 2019;460:1-9. [PMID: 31207320 DOI: 10.1016/j.canlet.2019.114428] [Cited by in Crossref: 94] [Cited by in F6Publishing: 101] [Article Influence: 23.5] [Reference Citation Analysis]
400 Yang S, Zhu H, Cheng Q. Correlative analysis of miR-34b and p53 with pathological characteristics of NSCLC. Oncol Lett 2019;17:5558-64. [PMID: 31186777 DOI: 10.3892/ol.2019.10239] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
401 Yin J, Hu W, Pan L, Fu W, Dai L, Jiang Z, Zhang F, Zhao J. let‑7 and miR‑17 promote self‑renewal and drive gefitinib resistance in non‑small cell lung cancer. Oncol Rep 2019;42:495-508. [PMID: 31233201 DOI: 10.3892/or.2019.7197] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
402 Weidle UH, Birzele F, Nopora A. MicroRNAs as Potential Targets for Therapeutic Intervention With Metastasis of Non-small Cell Lung Cancer. Cancer Genomics Proteomics 2019;16:99-119. [PMID: 30850362 DOI: 10.21873/cgp.20116] [Cited by in Crossref: 30] [Cited by in F6Publishing: 40] [Article Influence: 7.5] [Reference Citation Analysis]
403 Zhang JT, Lin YC, Xiao BF, Yu BT. Overexpression of Family with Sequence Similarity 83, Member A (FAM83A) Predicts Poor Clinical Outcomes in Lung Adenocarcinoma. Med Sci Monit 2019;25:4264-72. [PMID: 31175804 DOI: 10.12659/MSM.910804] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
404 Ku BM, Bae YH, Lee KY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. Invest New Drugs 2020;38:360-8. [PMID: 31124056 DOI: 10.1007/s10637-019-00795-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
405 Garcia J, Wozny AS, Geiguer F, Delherme A, Barthelemy D, Merle P, Tissot C, Jones FS, Johnson C, Xing X, Xu Z, Edelstein DL, Brevet M, Souquet PJ, Rodriguez-Lafrasse C, Payen L, Couraud S. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells. Cancer Med 2019;8:3685-97. [PMID: 31112372 DOI: 10.1002/cam4.2244] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
406 Wang X, Li W, Zhang N, Zheng X, Jing Z. Opportunities and challenges of co-targeting epidermal growth factor receptor and autophagy signaling in non-small cell lung cancer. Oncol Lett 2019;18:499-506. [PMID: 31289521 DOI: 10.3892/ol.2019.10372] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
407 Evans DM, Fang J, Silvers T, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, Bowles L, Connelly J, Harris E, Krushkal J, Rubinstein L, Doroshow JH, Teicher BA. Exposure time versus cytotoxicity for anticancer agents. Cancer Chemother Pharmacol 2019;84:359-71. [PMID: 31102023 DOI: 10.1007/s00280-019-03863-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
408 Zhou S, Gravekamp C, Bermudes D, Liu K. Tumour-targeting bacteria engineered to fight cancer. Nat Rev Cancer 2018;18:727-43. [PMID: 30405213 DOI: 10.1038/s41568-018-0070-z] [Cited by in Crossref: 240] [Cited by in F6Publishing: 254] [Article Influence: 60.0] [Reference Citation Analysis]
409 Wang Y, Zhang J, Ren S, Sun D, Huang H, Wang H, Jin Y, Li F, Zheng C, Yang L, Deng L, Jiang Z, Jiang T, Han X, Hou S, Guo C, Li F, Gao D, Qin J, Gao D, Chen L, Wong K, Li C, Hu L, Zhou C, Ji H. Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors.. [DOI: 10.1101/638007] [Reference Citation Analysis]
410 Ramón Y Cajal S, Hümmer S, Peg V, Guiu XM, De Torres I, Castellvi J, Martinez-Saez E, Hernandez-Losa J. Integrating clinical, molecular, proteomic and histopathological data within the tissue context: tissunomics. Histopathology 2019;75:4-19. [PMID: 30667539 DOI: 10.1111/his.13828] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
411 Chantarawong W, Kuncharoen N, Tanasupawat S, Chanvorachote P. Lumichrome Inhibits Human Lung Cancer Cell Growth and Induces Apoptosis via a p53-Dependent Mechanism. Nutr Cancer 2019;71:1390-402. [PMID: 31074646 DOI: 10.1080/01635581.2019.1610183] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
412 Li T, Zhang F, Qin P, Wang Y, Wang A, Zhao L, Xu B, Gao Q. Exploring a Tumor-Intrinsic PD-L1 Signal with Proximity-Dependent Biotin Identification in Lung Cancer Cells. Biochemistry 2019;58:2293-6. [PMID: 31021072 DOI: 10.1021/acs.biochem.9b00113] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
413 Liang S, Chao S, Li C, Ip K, Lin Y, Hsu C, Hsu P, Wang I. Foxm1 Transcription Factor Regulates Lung Adenocarcinoma Development. IOP Conf Ser : Earth Environ Sci 2019;276:012003. [DOI: 10.1088/1755-1315/276/1/012003] [Reference Citation Analysis]
414 Tahmasebi-Birgani MJ, Teimoori A, Ghadiri A, Mansoury-Asl H, Danyaei A, Khanbabaei H. Fractionated radiotherapy might induce epithelial-mesenchymal transition and radioresistance in a cellular context manner. J Cell Biochem 2019;120:8601-10. [PMID: 30485518 DOI: 10.1002/jcb.28148] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
415 Mitsudomi T. BRAF Fusion - Another Mechanism of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol 2019;14:764-5. [PMID: 31027740 DOI: 10.1016/j.jtho.2019.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
416 Li Y, Wu F, Tan Q, Guo M, Ma P, Wang X, Zhang S, Xu J, Luo P, Jin Y. The multifaceted roles of FOXM1 in pulmonary disease. Cell Commun Signal 2019;17:35. [PMID: 30992007 DOI: 10.1186/s12964-019-0347-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
417 McCoach CE, Bivona TG. Engineering Multidimensional Evolutionary Forces to Combat Cancer. Cancer Discov 2019;9:587-604. [PMID: 30992280 DOI: 10.1158/2159-8290.CD-18-1196] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
418 Cryer AM, Chan C, Eftychidou A, Maksoudian C, Mahesh M, Tetley TD, Spivey AC, Thorley AJ. Tyrosine Kinase Inhibitor Gold Nanoconjugates for the Treatment of Non-Small Cell Lung Cancer. ACS Appl Mater Interfaces 2019;11:16336-46. [DOI: 10.1021/acsami.9b02986] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
419 Gu X, Qiu Y, Lin M, Cui K, Chen G, Chen Y, Fan C, Zhang Y, Xu L, Chen H, Wan J, Lu W, Xiao Z. CuS Nanoparticles as a Photodynamic Nanoswitch for Abrogating Bypass Signaling To Overcome Gefitinib Resistance. Nano Lett 2019;19:3344-52. [DOI: 10.1021/acs.nanolett.9b01065] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
420 Mao S, Li Y, Lu Z, Che Y, Huang J, Lei Y, Wang Y, Liu C, Wang X, Zheng S, Sun N, He J. PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing. Cancer Med 2019;8:2429-41. [PMID: 30932358 DOI: 10.1002/cam4.2115] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
421 Jiang W, Ji M. Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer. Semin Cancer Biol 2019;59:3-22. [PMID: 30943434 DOI: 10.1016/j.semcancer.2019.03.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
422 Chen Z, Tian D, Liao X, Zhang Y, Xiao J, Chen W, Liu Q, Chen Y, Li D, Zhu L, Cai S. Apigenin Combined With Gefitinib Blocks Autophagy Flux and Induces Apoptotic Cell Death Through Inhibition of HIF-1α, c-Myc, p-EGFR, and Glucose Metabolism in EGFR L858R+T790M-Mutated H1975 Cells. Front Pharmacol 2019;10:260. [PMID: 30967777 DOI: 10.3389/fphar.2019.00260] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
423 Lin C, Shi X, Yang S, Zhao J, He Q, Jin Y, Yu X. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer. Lung Cancer 2019;131:62-8. [PMID: 31027700 DOI: 10.1016/j.lungcan.2019.03.018] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 12.5] [Reference Citation Analysis]
424 Wilson FH, Herbst RS. Larotrectinib in NTRK-Rearranged Solid TumorsPublished as part of the Biochemistry series "Biochemistry to Bedside". Biochemistry 2019;58:1555-7. [PMID: 30865435 DOI: 10.1021/acs.biochem.9b00126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
425 Lin PC, Yeh YM, Wu PY, Hsu KF, Chang JY, Shen MR. Germline susceptibility variants impact clinical outcome and therapeutic strategies for stage III colorectal cancer. Sci Rep 2019;9:3931. [PMID: 30850667 DOI: 10.1038/s41598-019-40571-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
426 Jiang L, Guo F, Liu X, Li X, Qin Q, Shu P, Li Y, Wang Y. Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC. Sci Rep 2019;9:3705. [PMID: 30842489 DOI: 10.1038/s41598-018-38068-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
427 Zhou L, Li M, Yu X, Gao F, Li W. Repression of Hexokinases II-Mediated Glycolysis Contributes to Piperlongumine-Induced Tumor Suppression in Non-Small Cell Lung Cancer Cells. Int J Biol Sci 2019;15:826-37. [PMID: 30906213 DOI: 10.7150/ijbs.31749] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 7.3] [Reference Citation Analysis]
428 Chatterjee N, Bivona TG. Polytherapy and Targeted Cancer Drug Resistance. Trends Cancer 2019;5:170-82. [PMID: 30898264 DOI: 10.1016/j.trecan.2019.02.003] [Cited by in Crossref: 98] [Cited by in F6Publishing: 107] [Article Influence: 24.5] [Reference Citation Analysis]
429 Sulé-Suso J, Watson NA, van Pittius DG, Jegannathen A. Striking lung cancer response to self-administration of cannabidiol: A case report and literature review. SAGE Open Med Case Rep 2019;7:2050313X19832160. [PMID: 30815264 DOI: 10.1177/2050313X19832160] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
430 Cryer AM, Thorley AJ. Nanotechnology in the diagnosis and treatment of lung cancer. Pharmacol Ther 2019;198:189-205. [PMID: 30796927 DOI: 10.1016/j.pharmthera.2019.02.010] [Cited by in Crossref: 62] [Cited by in F6Publishing: 69] [Article Influence: 15.5] [Reference Citation Analysis]
431 Wen Q, Jiao X, Kuang F, Hou B, Zhu Y, Guo W, Sun G, Ba Y, Yu D, Wang D, Zhang F, Qiao HC, Wang S, Tang S, Qiao H. FoxO3a inhibiting expression of EPS8 to prevent progression of NSCLC: A new negative loop of EGFR signaling. EBioMedicine 2019;40:198-209. [PMID: 30738830 DOI: 10.1016/j.ebiom.2019.01.053] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
432 Page A, Ortega A, Alameda JP, Navarro M, Paramio JM, Saiz-Pardo M, Almeida EI, Hernández P, Fernández-Aceñero MJ, García-Fernández RA, Casanova ML. IKKα Promotes the Progression and Metastasis of Non-Small Cell Lung Cancer Independently of its Subcellular Localization. Comput Struct Biotechnol J 2019;17:251-62. [PMID: 30867890 DOI: 10.1016/j.csbj.2019.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
433 Zhao S, Li X, Zhao C, Jiang T, Jia Y, Shi J, He Y, Li J, Zhou F, Gao G, Li W, Chen X, Su C, Ren S, Zhou C. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M. Lung Cancer 2019;128:33-9. [DOI: 10.1016/j.lungcan.2018.12.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
434 Zhao G, Gong L, Su D, Jin Y, Guo C, Yue M, Yao S, Qin Z, Ye Y, Tang Y, Wu Q, Zhang J, Cui B, Ding Q, Huang H, Hu L, Chen Y, Zhang P, Hu G, Chen L, Wong KK, Gao D, Ji H. Cullin5 deficiency promotes small-cell lung cancer metastasis by stabilizing integrin β1. J Clin Invest 2019;129:972-87. [PMID: 30688657 DOI: 10.1172/JCI122779] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
435 Sabnis AJ, Bivona TG. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends Mol Med. 2019;25:185-197. [PMID: 30686761 DOI: 10.1016/j.molmed.2018.12.009] [Cited by in Crossref: 68] [Cited by in F6Publishing: 78] [Article Influence: 17.0] [Reference Citation Analysis]
436 Yao J, Ly D, Dervovic D, Fang L, Lee JB, Kang H, Wang YH, Pham NA, Pan H, Tsao MS, Zhang L. Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15. J Immunother Cancer 2019;7:17. [PMID: 30670085 DOI: 10.1186/s40425-019-0507-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
437 Zhang Q, Xiao M, Gu S, Xu Y, Liu T, Li H, Yu Y, Qin L, Zhu Y, Chen F, Wang Y, Ding C, Wu H, Ji H, Chen Z, Zu Y, Malkoski S, Li Y, Liang T, Ji J, Qin J, Xu P, Zhao B, Shen L, Lin X, Feng XH. ALK phosphorylates SMAD4 on tyrosine to disable TGF-β tumour suppressor functions. Nat Cell Biol 2019;21:179-89. [PMID: 30664791 DOI: 10.1038/s41556-018-0264-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
438 Day TF, Kallakury BVS, Ross JS, Voronel O, Vaidya S, Sheehan CE, Kasid UN. Dual Targeting of EGFR and IGF1R in the TNFAIP8 Knockdown Non-Small Cell Lung Cancer Cells. Mol Cancer Res 2019;17:1207-19. [PMID: 30647104 DOI: 10.1158/1541-7786.MCR-18-0731] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
439 Noor ZS, Goldman JW. EGFR Targeted Therapy. Targeted Therapies for Lung Cancer 2019. [DOI: 10.1007/978-3-030-17832-1_1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
440 Duffield E. Mechanisms of Acquired Resistance to Targeted Therapy in NSCLC: Role of Repeat Biopsy and Nursing Considerations. Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners 2019. [DOI: 10.1007/978-3-030-16550-5_6] [Reference Citation Analysis]
441 Heng WS, Gosens R, Kruyt FAE. Lung cancer stem cells: origin, features, maintenance mechanisms and therapeutic targeting. Biochem Pharmacol 2019;160:121-33. [PMID: 30557553 DOI: 10.1016/j.bcp.2018.12.010] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 10.6] [Reference Citation Analysis]
442 Neel DS, Allegakoen DV, Olivas V, Mayekar MK, Hemmati G, Chatterjee N, Blakely CM, McCoach CE, Rotow JK, Le A, Karachaliou N, Rosell R, Riess JW, Nichols R, Doebele RC, Bivona TG. Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins. Cancer Res 2019;79:546-56. [PMID: 30538120 DOI: 10.1158/0008-5472.CAN-18-1492] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
443 Jiang T, Zhao J, Zhao C, Li X, Shen J, Zhou J, Ren S, Su C, Zhou C, O'Brien M. Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated With First-Line EGFR Tyrosine Kinase Inhibitors. Clin Lung Cancer 2019;20:124-133.e2. [PMID: 30587399 DOI: 10.1016/j.cllc.2018.11.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
444 Zhou L, Yi Y, Yuan Q, Zhang J, Li Y, Wang P, Xu M, Xie S. VAOS, a novel vanadyl complexes of alginate saccharides, inducing apoptosis via activation of AKT-dependent ROS production in NSCLC. Free Radical Biology and Medicine 2018;129:177-85. [DOI: 10.1016/j.freeradbiomed.2018.09.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
445 Berger L, Janning M, Velthaus J, Ben-batalla I, Schatz S, Falk M, Iglauer P, Simon R, Cao R, Forcato C, Manaresi N, Bramlett K, Buson G, Hanssen A, Tiemann M, Sauter G, Bokemeyer C, Riethdorf S, Reck M, Pantel K, Wikman H, Loges S. Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. Journal of Thoracic Oncology 2018;13:e243-6. [DOI: 10.1016/j.jtho.2018.08.2025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
446 Patel SA, Minn AJ. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. Immunity 2018;48:417-33. [PMID: 29562193 DOI: 10.1016/j.immuni.2018.03.007] [Cited by in Crossref: 285] [Cited by in F6Publishing: 309] [Article Influence: 57.0] [Reference Citation Analysis]
447 Camolotto SA, Pattabiraman S, Mosbruger TL, Jones A, Belova VK, Orstad G, Streiff M, Salmond L, Stubben C, Kaestner KH, Snyder EL. FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer. Elife 2018;7:e38579. [PMID: 30475207 DOI: 10.7554/eLife.38579] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
448 Parascandolo A, Laukkanen MO. Carcinogenesis and Reactive Oxygen Species Signaling: Interaction of the NADPH Oxidase NOX1-5 and Superoxide Dismutase 1-3 Signal Transduction Pathways. Antioxid Redox Signal 2019;30:443-86. [PMID: 29478325 DOI: 10.1089/ars.2017.7268] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 9.2] [Reference Citation Analysis]
449 Li Q, Ma W, Li T. Sortilin as a new membrane inhibitor of EGFR trafficking for overcoming resistance to EGFR inhibitors in non-small cell lung cancer. J Thorac Dis 2018;10:S3186-91. [PMID: 30430029 DOI: 10.21037/jtd.2018.08.25] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
450 Liu D, Li X, Chen X, Sun Y, Tang A, Li Z, Zheng J, Shi M. Neural regulation of drug resistance in cancer treatment. Biochim Biophys Acta Rev Cancer 2019;1871:20-8. [PMID: 30419311 DOI: 10.1016/j.bbcan.2018.10.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
451 Huang H. Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces. Int J Mol Sci 2018;19:E3448. [PMID: 30400214 DOI: 10.3390/ijms19113448] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
452 Yoon S, Choi CM, Lee JC. The different path of T790M-positive EGFR-mutant lung cancer. Ann Transl Med 2018;6:S47. [PMID: 30613622 DOI: 10.21037/atm.2018.10.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
453 Lu GS, Li M, Xu CX, Wang D. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma. Cell Death Dis 2018;9:1111. [PMID: 30382076 DOI: 10.1038/s41419-018-1162-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
454 Relli V, Trerotola M, Guerra E, Alberti S. Distinct lung cancer subtypes associate to distinct drivers of tumor progression. Oncotarget 2018;9:35528-40. [PMID: 30473748 DOI: 10.18632/oncotarget.26217] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
455 Bergado Báez G, Hernández Fernández DR, Mazorra Herrera Z, Sánchez Ramírez B. HER1-based vaccine: Simultaneous activation of humoral and cellular immune response. Semin Oncol 2018;45:75-83. [PMID: 30318087 DOI: 10.1053/j.seminoncol.2018.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
456 Yin W, Yu X, Kang X, Zhao Y, Zhao P, Jin H, Fu X, Wan Y, Peng C, Huang Y. Remodeling Tumor-Associated Macrophages and Neovascularization Overcomes EGFRT790M -Associated Drug Resistance by PD-L1 Nanobody-Mediated Codelivery. Small 2018;14:e1802372. [PMID: 30307695 DOI: 10.1002/smll.201802372] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
457 van Veggel B, de Langen AJ, Hashemi S, Monkhorst K, Rosenberg EH, Heideman DA, Radonic T, Smit EF. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses. Lung Cancer 2018;124:130-4. [DOI: 10.1016/j.lungcan.2018.07.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
458 Cadranel J, Fallet V, Canellas A, Lavolé A, Ruppert A, Wislez M. Prise en charge thérapeutique des cancers bronchiques non à petites cellules de stades avancés mutés pour l’EGFR. Revue des Maladies Respiratoires Actualités 2018;10:425-439. [DOI: 10.1016/s1877-1203(18)30040-5] [Reference Citation Analysis]
459 Su PL, Wu YL, Chang WY, Ho CL, Tseng YL, Lai WW, Su WC, Lin CC, Yang SC. Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer. Ther Adv Med Oncol 2018;10:1758835918797589. [PMID: 30263066 DOI: 10.1177/1758835918797589] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
460 Jiang P, Xu C, Chen L, Chen A, Wu X, Zhou M, Haq IU, Mariyam Z, Feng Q. EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells. Molecular Carcinogenesis 2018;57:1835-44. [DOI: 10.1002/mc.22901] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
461 Cao S, Wang Z, Gao X, He W, Cai Y, Chen H, Xu R. FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC. J Exp Clin Cancer Res 2018;37:220. [PMID: 30189871 DOI: 10.1186/s13046-018-0894-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 8.6] [Reference Citation Analysis]
462 Zhang Y, Zhang Q, Chen H, Wang C. BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway. Life Sciences 2018;208:284-94. [DOI: 10.1016/j.lfs.2018.07.023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
463 Rasheduzzaman M, Moon J, Lee J, Nazim UM, Park S. Telmisartan generates ROS-dependent upregulation of death receptor 5 to sensitize TRAIL in lung cancer via inhibition of autophagy flux. The International Journal of Biochemistry & Cell Biology 2018;102:20-30. [DOI: 10.1016/j.biocel.2018.06.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
464 Liu Z, Chen Z, Wang J, Zhang M, Li Z, Wang S, Dong B, Zhang C, Gao J, Shen L. Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance. J Hematol Oncol 2018;11:109. [PMID: 30157900 DOI: 10.1186/s13045-018-0651-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
465 Pine SR. Rethinking Gamma-secretase Inhibitors for Treatment of Non-small-Cell Lung Cancer: Is Notch the Target? Clin Cancer Res 2018;24:6136-41. [PMID: 30104200 DOI: 10.1158/1078-0432.CCR-18-1635] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
466 Zhao D, Hou H, Zhang X. Progress in the treatment of solid tumors with apatinib: a systematic review. Onco Targets Ther. 2018;11:4137-4147. [PMID: 30050305 DOI: 10.2147/ott.s172305] [Cited by in Crossref: 35] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
467 Addeo A, Metro G. First-line alectinib for ALK-positive lung cancer: is there room for further improvement? Drugs Context. 2018;7:212537. [PMID: 30023004 DOI: 10.7573/dic.212537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
468 Hsin I, Hsu J, Wu W, Lu H, Wu M, Ko J. GMI, a fungal immunomodulatory protein from Ganoderma microsporum , induce apoptosis via β-catenin suppression in lung cancer cells. Environmental Toxicology 2018;33:955-61. [DOI: 10.1002/tox.22582] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
469 Huang J, Weng T, Ko J, Chen NY, Xiang Y, Volcik K, Han L, Blackburn MR, Lu X. Suppression of cleavage factor Im 25 promotes the proliferation of lung cancer cells through alternative polyadenylation. Biochem Biophys Res Commun 2018;503:856-62. [PMID: 29928883 DOI: 10.1016/j.bbrc.2018.06.087] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
470 Clark TA, Chung JH, Kennedy M, Hughes JD, Chennagiri N, Lieber DS, Fendler B, Young L, Zhao M, Coyne M, Breese V, Young G, Donahue A, Pavlick D, Tsiros A, Brennan T, Zhong S, Mughal T, Bailey M, He J, Roels S, Frampton GM, Spoerke JM, Gendreau S, Lackner M, Schleifman E, Peters E, Ross JS, Ali SM, Miller VA, Gregg JP, Stephens PJ, Welsh A, Otto GA, Lipson D. Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. J Mol Diagn. 2018;20:686-702. [PMID: 29936259 DOI: 10.1016/j.jmoldx.2018.05.004] [Cited by in Crossref: 114] [Cited by in F6Publishing: 122] [Article Influence: 22.8] [Reference Citation Analysis]
471 Parker BM, Parker JV, Lymperopoulos A, Konda V. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma. J Oncol Pharm Pract. 2019;25:1226-1230. [PMID: 29925295 DOI: 10.1177/1078155218781944] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
472 Gong K, Guo G, Gerber DE, Gao B, Peyton M, Huang C, Minna JD, Hatanpaa KJ, Kernstine K, Cai L, Xie Y, Zhu H, Fattah FJ, Zhang S, Takahashi M, Mukherjee B, Burma S, Dowell J, Dao K, Papadimitrakopoulou VA, Olivas V, Bivona TG, Zhao D, Habib AA. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J Clin Invest 2018;128:2500-18. [PMID: 29613856 DOI: 10.1172/JCI96148] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 10.4] [Reference Citation Analysis]
473 Alam SK, Astone M, Liu P, Hall SR, Coyle AM, Dankert EN, Hoffman DK, Zhang W, Kuang R, Roden AC, Mansfield AS, Hoeppner LH. DARPP-32 and t-DARPP promote non-small cell lung cancer growth through regulation of IKKα-dependent cell migration. Commun Biol 2018;1:43. [PMID: 29782621 DOI: 10.1038/s42003-018-0050-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
474 Zaman A, Bivona TG. Emerging application of genomics-guided therapeutics in personalized lung cancer treatment. Ann Transl Med 2018;6:160. [PMID: 29911108 DOI: 10.21037/atm.2018.05.02] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
475 Oliveres H, Caglevic C, Passiglia F, Taverna S, Smits E, Rolfo C. Vaccine and immune cell therapy in non-small cell lung cancer. J Thorac Dis 2018;10:S1602-14. [PMID: 29951309 DOI: 10.21037/jtd.2018.05.134] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
476 Procházková J, Strapáčová S, Svržková L, Andrysík Z, Hýžďalová M, Hrubá E, Pěnčíková K, Líbalová H, Topinka J, Kléma J, Espinosa JM, Vondráček J, Machala M. Adaptive changes in global gene expression profile of lung carcinoma A549 cells acutely exposed to distinct types of AhR ligands. Toxicol Lett 2018;292:162-74. [PMID: 29704546 DOI: 10.1016/j.toxlet.2018.04.024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
477 Huang R, Zheng Y, Li C, Ding C, Xu C, Zhao J. MicroRNA-485-5p suppresses growth and metastasis in non-small cell lung cancer cells by targeting IGF2BP2. Life Sciences 2018;199:104-11. [DOI: 10.1016/j.lfs.2018.03.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 47] [Article Influence: 7.4] [Reference Citation Analysis]
478 Tong Y, Zhao Z, Liu B, Bao A, Zheng H, Gu J, McGrath M, Xia Y, Tan B, Song C, Li Y. 5'/ 3' imbalance strategy to detect ALK fusion genes in circulating tumor RNA from patients with non-small cell lung cancer. J Exp Clin Cancer Res 2018;37:68. [PMID: 29587818 DOI: 10.1186/s13046-018-0735-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
479 Andriani F, Majorini MT, Mano M, Landoni E, Miceli R, Facchinetti F, Mensah M, Fontanella E, Dugo M, Giacca M, Pastorino U, Sozzi G, Delia D, Roz L, Lecis D. MiR-16 regulates the pro-tumorigenic potential of lung fibroblasts through the inhibition of HGF production in an FGFR-1- and MEK1-dependent manner. J Hematol Oncol 2018;11:45. [PMID: 29558956 DOI: 10.1186/s13045-018-0594-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
480 Fu Y, Li C, Luo Y, Li L, Liu J, Gui R. Silencing of Long Non-coding RNA MIAT Sensitizes Lung Cancer Cells to Gefitinib by Epigenetically Regulating miR-34a. Front Pharmacol 2018;9:82. [PMID: 29487526 DOI: 10.3389/fphar.2018.00082] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 7.8] [Reference Citation Analysis]
481 D'Cunha J. The matrix revisited. J Thorac Cardiovasc Surg 2018;155:2176. [PMID: 29409616 DOI: 10.1016/j.jtcvs.2017.12.111] [Reference Citation Analysis]
482 Cadranel J. Osimertinib in first-line treatment-is a comparison not proof? Ann Transl Med 2018;6:57. [PMID: 29611546 DOI: 10.21037/atm.2017.12.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
483 Iwama E, Nakanishi Y, Okamoto I. Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer. Expert Rev Anticancer Ther 2018;18:267-76. [PMID: 29363369 DOI: 10.1080/14737140.2018.1432356] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
484 Kuhlmann L, Cummins E, Samudio I, Kislinger T. Cell-surface proteomics for the identification of novel therapeutic targets in cancer. Expert Review of Proteomics 2018;15:259-75. [DOI: 10.1080/14789450.2018.1429924] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
485 Bai Y, Chen X, Hou L, Qian J, Jiang T, Zhou C, Ciebiada M. PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs. Cancer Biol Med 2018;15:434-42. [PMID: 30766753 DOI: 10.20892/j.issn.2095-3941.2018.0223] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
486 Bryant JM, Bouchard M, Haque A. Anticancer Activity of Ganoderic Acid DM: Current Status and Future Perspective. J Clin Cell Immunol 2017;8:535. [PMID: 29399381 DOI: 10.4172/2155-9899.1000535] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
487 Alam SK, Astone M, Liu P, Hall SR, Coyle AM, Dankert EN, Hoffman DK, Zhang W, Kuang R, Roden AC, Mansfield AS, Hoeppner LH. DARPP-32 and t-DARPP promote lung cancer growth through IKKα-dependent cell migration and Akt/Erk-mediated cell survival.. [DOI: 10.1101/229658] [Reference Citation Analysis]
488 [DOI: 10.1101/396697] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Reference Citation Analysis]